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Delivering antibiotics through pulmonary is a promising approach for treatment of 
cystic fibrosis (CF). For the current marketed antibiotic formulations, however, the 
requirement of multiple drug administrations per day to achieve a therapeutic effect limits 
their applicability. To reduce administration frequency, controlled pulmonary release 
formulation is a strategy which can maintain effective and consistent local drug 
concentration and therefore prolong the time period between doses. However, these 
particles of controlled release formulation with optimum aerodynamic diameter range 
targeted to the alveolar region (i.e. 0.5<da<5 µm) will be rapidly cleared by the alveolar 
macrophages. This is because the geometric diameters of these particles are usually less 
than 6 µm, which is the preferable size range for alveolar macrophages’ uptake. 
To overcome the clearance of alveolar macrophages for the controlled release 
formulation, the approach we employed in the current study was to form swellable 
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hydrogel dry powder by utilizing the unique benefits of hydrogel, higher drug payload, 
larger geometric diameter after swelling, and sustained drug delivery. In the first study, 
based on the fact that ciprofloxacin could form hydrogel with alginate, a nano-in-micro 
hydrogel particle formulation was developed for sustained pulmonary drug delivery, 
which takes the advantages of both chitosan based nanoparticles and swellable and 
respirable alginate hydrogel particles. The dry nano-in-micro hydrogel particles exhibited 
a rapid initial swelling within 2 minutes, and showed sustained drug release pattern. 
When delivered to rats, it enabled ciprofloxacin to achieve a low systemic exposure but 
maintained higher concentrations in the lung for more than seven hours.  
In the second study, we directly combined ciprofloxacin with alginate to form 
hydrogel dry powder, without the addition of extra chitosan. In such way, we simplified 
the preparation method for hydrogel particles, decreased the potential risk of polymeric 
chitosan accumulation in the lung tissue, and increased the ciprofloxacin loading 
efficiency from 30% to 57% in the finial microsized alginate hydrogel dry powder.  
Ciprofloxacin was present in the amorphous state in the dry powder and was released in a 
controlled release manner relative to ciprofloxacin alone, i.e. 80% of drug released at 8 
hours. 
Despite aggressive antibiotic treatment, the elimination of chronic Pseudomonas 
aeruginosa (P. aeruginosa) infections in CF lungs is extremely difficult. The pathogen 
often adapts to resist both the host inflammatory defense mechanisms and externally 
applied antibiotic therapy, often allowing for the formation of microbial biofilms. The 
resulting biofilms are thick, pathogen embedded, and highly resistant to common 
therapeutic agents currently used in CF infections. Thus, the development of newer 
x 
 
antimicrobial agents with superior abilities to eliminate the established chronic biofilm 
associated with CF infections remains the utmost priority in CF therapy. A conventional 
antibiotic, tobramycin was chemically modified. Tobramycin has previously been 
demonstrated to bind to biofilm matrices, thus reducing the effective concentration of 
antimicrobial able to reach the pathogenic organisms, as well as limiting the penetration 
of the antibacterial agent to the deeper microstructure of the biofilm, thereby creating an 
undesirable stress response in the pathogen. Modification of antimicrobial as by 
PEGylation appears to be a promising approach for overcoming the bacterial resistance in 
the established biofilms of Pseudomonas aeruginosa. 
This body of work provides two promising strategies of delivering antibiotics via 
pulmonary route for the treatment of cystic fibrosis. The first strategy is to form 
controlled release formulation, typically as swellable hydrogel dry powder, which could 
sustain the drug release, and swell to larger size as to avoid the alveolar macrophage 
uptake as to increase the local retention period. The second strategy is related to the 
biofilm resistance. By modifying the existent antibiotic to reduce the binding efficacy to 
the extracellular matrix of biofilm, more antibiotic could subsequently enter into the inner 
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Inhalation therapy has long been used by humans to treat diseases in the 
respiratory tract. The primary reason for selecting this method of drug delivery is the 
ability for the regional targeting of the respiratory tract for local diseases (e.g. asthma, 
chronic obstructive pulmonary disease, cystic fibrosis). This allows rapid therapeutic 
onset (i.e. during acute asthma attack), minimal incidence of systemic side effects (e.g. 
broad side effects observed with long term use of corticosteroids), and achievement of 
much higher concentrations at the respiratory region (e.g. lung infections). Additionally, 
the lung contains much lower concentrations of metabolizing enzymes than other portals 
of entry, especially the gastrointestinal tract, which decreases the likelihood of the 
degradation of drug. Combining a high surface area (70 – 100 m
2
), good permeability 
through the thin epithelial cell layer and the small fluid volume on the absorption surface 
in the peripheral respiratory region, small molecules can be rapidly absorbed into the 
blood stream. These characteristics have led to a number of very successful therapeutic 
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These attributes, however, have also lead to the administration of other compounds via 
the lung typically via smoke inhalation. Nicotine administration, for example, is an 
excellent example of an early form of drug delivery (though non-therapeutic) that allows 
the user to accurately titrate pharmacokinetics. Smoking of course is where pulmonary 
drug delivery began.  
1.2 HISTORY AND RATIONALE OF PULMONARY DRUG DELIVERY 
The origins of pulmonary drug delivery may be traced back to at least 4000 years 
ago in Ayurvedic medicine. During this time in India, many respiratory illnesses were 
treated by smoking a pipe smeared with a paste made out of the Datura species and other 
herbs. Ancient Egyptians also used to place black henbane, plant of the Hyosycamus 
muticus species containing the anticholinergic compound, hysocyamine, on hot bricks 
and inhale its vapor (1).  
In 1778, John Mudge, an English physician coined the word “inhaler” and 
published a design of a remedial inhaler (1). His design was widely accepted and used in 
the ceramic inhalers popularized in the 19
th
 century. 
Modern inhalers were introduced with the pressured metered dose inhalers 
(pMDIs) that were first developed in the 1950s as an alternative to early nebulizers. A 
pMDI is a device that delivers medication to the respiratory system, in the form of an 
aerosol spray generated by forcing a liquid through a nozzle under pressure. It consists of 
a drug dissolved or suspended in a propellant, a liquefied compressed gas. The first pMDI 
was developed in Riker Laboratories, Inc (now 3M Pharmaceuticals, St. Paul, Minnesota) 
in 1955. The development was initiated by Dr. George Maison, president of Riker Labs, 
who licensed a patent on a metering valve invented by Mr. Meshburg. While the 
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Meshburg valve was initially intended for perfume aerosols, Dr. Maison’s asthmatic 
daughter suggested the potential use for it in pharmaceutical inhalation therapy. More 
recently, dry powder inhalers (DPIs) have become commonplace. These devices have 
emerged from the environmental concerns associated with the pMDIs. The transition 
from the chlorofluorocarbons (CFCs) to hydrofluoroalkane (HFCs) was not straight 
forward and therefore several large pharma companies opted to have DPI development 
capabilities. These devices are generally patient activated rather than device activated and 
therefore do not suffer from issues of inhalation coordination with actuation of the 
aerosol. They also have the ability to have improved stability, increased administration 
dose, and have shown to have marketing benefits. Advair™ for example, is a 
combination drug DPI that has been a commercial success, $4.7 billion in 2010.  
1.3 CURRENT PRODUCTS AND DISEASES 
1.3.1 Asthma  
Asthma  is an inflammatory disease associated with reversible narrowing of the 
bronchial airways (2). The exact causes of asthma have not yet been determined but are 
likely linked to the environment, genetics and biology. Asthma affects more than 22 
million people in the United States and 300 million people worldwide. It results in the 
deaths of approximately 255,000 people globally each year. 
The treatment of asthma can be broadly divided into two categories based on the 
drug’s effect.  Firstly, bronchodilators induce relaxation of the airway smooth muscle. 
Secondly, anti-inflammatory agents are used to treat underlying airway inflammation. In 
practical terms, however, clinicians prefer to classify these medicines with respect to their 
treatment onset time, i.e. relievers (acute use and effects) and preventers/controllers 
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(chronic use and effects) respectively.  
Short-Acting β-agonists, including albuterol, levalbuterol, and pirbuterol are 







 HFA), or solution for nebulization 
(AccuNeb
®
). Long-acting β agonists (LABAs) act in the similar mechanism as short-
acting β agonists, which can reduce the inflammation and open the airway. However, the 










in a single dose dry powder inhaler.  Long-term control medicines are used to reduce the 
chronic inflammation in airways. Types of long-term control drugs include: inhaled 
corticosteroids, leukotriene modifiers, long-acting beta agonists (LABAs), and 
theophylline. Inhaled corticosteroids have shown the greatest effect in controlling asthma 
symptoms, because they exhibit multiplicity of anti-inflammatory activities via the 
transcription of genes (4, 5). As with most asthma therapeutics, there are different 
formulations available for corticosteroids. Firstly, in the form of HFC metered-dose 





budisonide with formoterol (Symbicort
®
), and Fluticasone and Salmeterol (Advair
®
). 







), Fluticasone and Salmeterol (Advair 
Diskus®). More detailed information on marketed products, information in the following 
reference provides a current review (2, 5).  
1.3.2 Chronic obstructive pulmonary disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is referred as a group of lung 
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diseases, including chronic bronchitis and emphysema. Most patients with COPD have 
both conditions at the same time. Commonly there are three causes of COPD, including 
smoking, inhaled toxins or other irritants, and genetic predisposition. The damage caused 
in lungs cannot be reversed in COPD, therefore controlling symptoms and minimizing 
further damage is the main objective of the treatment (6); The most important approach 
for patients is smoking cessation (7). Medicines used to treat COPD include 
bronchodilators, inhaled steroids, antibiotics and vaccines. 
Bronchodilators can relax the smooth muscles around airways, making breathing 
easier. These medicines commonly used in treating COPD were listed in reference (8). 
Other treatments include antibiotics, anti-inflammatory, vaccines, mucolytic agents, 
antioxidant agents, etc. 
1.3.3 Cystic fibrosis 
Cystic fibrosis is a genetic disease caused by the mutation of the cystic fibrosis 
transmembrane regulator gene (CFTR), leading to the abnormal movement of ion and 
water in the airway epithelial. Consequently, the patients with cystic fibrosis will 
experience the accumulation of mucus, bacterial infection, inflammation, and even tissue 
destruction (9). Currently, there is not a specific cure for cystic fibrosis. 
Pulmonary infections are the common disease manifestation observed in patients 
with cystic fibrosis. Antibiotics, either taken by oral or, more commonly, via inhalation 
are typical treatments. Nebulized tobramycin and colistin are the choices for the 
treatment of infection caused by the P.aeruginosa. A significant problem is the deposition 
of those antibiotics, since most of them were found in the conductive zone instead of 
respiratory zone (10). Tobramycin and colistin in dry powder inhaler formulations offered 
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a new approach to the treatment of infection (10-12). Aztreonam lysine (13-15), which is 
a monobactam antibiotic for Gram-negative organisms, is taken in the form of 
nebulization, and is under phase III study (10).  
In addition to treatment of infections, CF patients may receive muco-active 
agents. Thick mucus is generally observed in the lungs, and its accumulation facilitates 
infection and inflammation. Currently, two choices are available to control airway mucus 
aiming to thin the mucus to allow for easier clearance. Acetadote
®
, which contains the 
acetylcysteine as the active ingredient, disrupts the intermolecular bonds of the mucus 
polymer, thus lowering the viscosity and elasticity of the mucus. Dornase Alfa, 
commercially named as Pulmozyme
®
, is administered via nebulization and can reduce the 
viscosity of cystic fibrosis sputum in a dose dependent manner by cleaving the DNA 
present in the airway mucus (16-18). Other candidates are the gelsolin and thymosin, 
which are both in development. Mannitol has been used to improve hydration of airway 
mucus via a hyper-osmotic effect, resulting in the decreasing of the viscosity of airway 
mucus. This product, along with nebulized hypertonic saline in now approved for use in 
many countries.  
Due to the genetic cause of cystic fibrosis, many researchers have therefore 
focused on gene therapy. Development of a successful gene therapy has been 
problematic. A complex composed of DNA and cationic lipids, which was delivered 
through aerosolization or direct instillation, showed a limited improvement in the 
treatment of cystic fibrosis (9, 19). Virus vectors, yielding a high transfection rates, have 
been limited because of the immunogenic issues (20-22). Despite the lack of practical 




1.4 RATIONAL FOR DEVELOPING POLYMER BASED PULMONARY 
DELIVERY SYSTEMS 
Few polymers are currently used in commercially available aerosol formulations. 
In particular, the pulmonary route is characterized by the few excipients that are found in 
approved products. However, despite the lack of commercialization of polymeric systems 
for lung delivery there has grown a large body of research that has focused on polymeric 
drug delivery systems for airway administration.   
1.4.1 Drug Protection 
Almost all of the metabolizing enzymes that exist in the liver are also found in the 
lungs, but often at lower levels. In addition, the metabolizing activity of those enzymes in 
the lungs is lower than the liver (23). However, many inhaled drugs are regarded as 
substrates of enzymes existed in lungs, for example: budesonide, salmeterol (24), and 
ciclesonide (23, 25, 26).  
Owing to these issues of local metabolism, polymers may be employed to protect 
drugs from enzymatic degradation, increasing local or even systemic bioavailability 
where appropriate. For example, poly (l-lactic acid) (PLA) coated budesonide, delivered 
through the intratracheal instillation to rats, showed a sustained release profile and a 
higher pulmonary-targeted effects (27). Additionally, another group used PEG(5000)-
DSPE polymeric micelles containing budesonide, which was compared to Pulmicort 
Respules
®
. And the in vivo study indicated a longer period of inhibition toward 
inflammatory cells in the asthmatic rats (28). 
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It is well known that insulin is sensitive to enzymatic degradation, and several 
researchers have attempted to develop inhaled insulin systems. For instance, one group 
developed an insulin loaded polybutylcyanoacrylate nanoparticle system which was also 
delivered via the intratracheal route. Compared with insulin solution, these polymeric 
particles significantly prolonged the pharmacodynamic action of insulin toward plasma 
glucose levels (29).  
In gene delivery, prevention of degradation of the gene prior to its targeting 
specific cells is an important objective. Polymeric formulations have therefore been 
applied in gene delivery. For example, researchers developed an acid degradable cationic 
polymer, which enabled condensation of anionic DNA. In contrast to naked DNA, these 
degradable polymers could achieve a significantly enhanced gene expression (30).  
Similar with DNA, siRNA is degraded quickly in biological environments such as 
the plasma and cellular cytoplasm (31). Ensuring siRNA stability during transit to the 
target site is one the major challenges that remains to be overcome for successful delivery 
of these molecules. As such, appropriate formulation systems are needed for stabilizing 
siRNA, enhancing the retention time in the lung region, and improving therapeutic effect. 
With this aim, polymers have also been applied for pulmonary siRNA delivery. Chitosan, 
which is well explored for drug delivery systems, has been regarded as a good candidate 
for gene delivery, because of its protection on siRNA, and improvement on genetic 
transfection (32-35). Other polymers used widely in the siRNA delivery included PLGA 
(36-38). 
Besides enzymatic degradation, another two main factors influencing the fate of 
drugs are mucociliary clearance and alveolar macrophage uptake. To avoid the 
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mucociliary clearance, the commonly adopted method is to utilize the mucoadhesive 
polymers such as chitosan (39-41) and PLGA (42) or to avoid the muco-ciliary escalator 
by aerodynamically targeting the deeper regions of the lungs. Mucoadhesive polymers 
would adhere to the mucus for a longer period, and hence increase the retention time in 
the respiratory system. In addition, PEG seems to prolong the residence time of the drugs 
in lungs by reducing their degradation and engulfment by alveolar macrophages (43). 
Conjugation  to 5 kDa poly(ethylene glycol) (44), has also been shown to facilitate 
particle penetration of human mucus, potentially decreasing the effect of mucociliary 
clearance.  
In the case of avoiding alveolar macrophage clearance, one way is to form the 
larger porous particle with polymer (45-48), since larger porous particle exhibited a 
suitable aerodynamic diameter which allows the particle reach into the deep lung while 
its geometric size is not optimal for macrophage to uptake. Another way is to get aid of 
endogenous agents, such as hyaluronic acid (HA). A study, in which an inhaled 
microparticle system was formulated through co-spray drying of insulin and HA, showed 
that this system displayed a longer mean residence time (MRT) and terminal half-life 
(t1/2) compared to spray dried pure insulin (49).  
1.4.2 Drug release and targeting 
Application of polymeric particles in drug delivery through pulmonary routes has 
been reasonably well studied due to the several advantages that is offered by this 
approach including for example sustained release, reduced dosing frequency, proper 
aerodynamic size and good bioavailability.  
Polymers used for aerosol formulations can be divided into two categories based 
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on their origin. The first type is natural polymers, for example: albumin, carrageenan, 
chitosan, gelatin, and hyaluronic acid. The other type are synthetic polymers, including 
for example poly (lactic acid), oligo (lactic acid), poly (vinyl alcohol), and acrylic acid 
derivatives (50). 
Additionally, polymers are usually deployed as particulate systems as either 
nanopartilces or microparticles. Compared with oral administration or injection, 
nanoparticle delivery to the lungs is less advanced from a development stage piont of 
view. The primary depostion mechanism of nanoparticle sized aerosols in the respiratory 
tract is via Brownian motion. Due to this longer times are needed to increase the 
depostion efficiencies and to avoid exhalation of the nano-aerosols (51, 52). In addition, 
generation of sufficient numbers of nanoparticles that carry a sufficient payload of drug is 
quite challenging. However, due to the wide and tunable properties of many polymers 
there is intensive research efforts now directed toward using the polymeric nanoparticles 
in the lung. Nanoparticles administered to the airways are often incorporated into the 
microparticles. Through specific manufacture methods such as spray-drying, the 
combined formulation facilitates appropriate aerodynamic diameters for lung delivery 
while taking advantage of some of the potential advantages of nanoparticles (53, 54). 
These advantages may include size dependent phenomena. For example, nanoparticles 
with a size lower than 150nm, experience delayed lung clearance, and may facilitate 
increased drug absorption compared with larger particles (55, 56). Several polymeric 
nanoparticle systems for pulmonary drug delivery have been recently reviewed (51).  
In contrast to polymeric nanoparticles, polymeric microparticles have seen 
broader applications thus far primarily due to their higher drug loading capacity. Many 
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studies have shown that microparticles were good carrier candidates for pulmonary drug 
delivery (57-59).  
Polymeric systems have been shown to improve the duration of effect of inhaled 
drugs either for local or systemic therapy (46, 60, 61). Generally, the sustained or 
controlled release of active agents from polymeric carriers depends on their distribution 
within the particles and the degradation rate of the polymer. Clearly the release 
mechanims of polymeric delivery systems depolyed in the pulmonary route will be 
similar to those used in classical controlled release drug delivery applications. 
Specifically three release mechanisms may be reponsible for drug release from these 
systems, including drug diffusion, polymer swelling followed by diffusion and polymer 
degradation (62) .  
In the situation of drug diffusion, the polymer systems are stable and have a 
general absence of swelling and degradation, such that the drug molecules pass through 
the polymeric matix to be released (62-64). In the case of swelling polymers, the 
polymers take up fluid from the environment, leading to matrix swelling. The increased 
pore size in the matrix subsequently facilitates drug transportation from the delivery 
system. When the polymers degraded in the medium due to hydrolysis or bulk erosion, 
the release of the drug is accompanied with the decreasing of molecular weight of 
polymers (62).  
 
1.4.3 Vaccines (41) 
Respiratory tract is a main route for many pathogens to enter into the human body, 
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causing short or chronic diseases (65-69). Because of its large surface area in the alveolar 
region and thin epithelial surfarce that is heavily monitored by the immune system, it is a 
promising region to target vaccines. A large number of alveolar macrophages and 
dendritic cells exist in the deep lung and may result in excellent immune responses. Even 
so, a question remains in pulmonary vaccination as to the deposition site of antigen in the 
respiratory tract. Many vaccines delivered via intranasal route have been developed (70, 
71). Intranasal vaccination is dependent on targeting the relatively smaller surface area in 
this region and the complexity of the nasal geometry The main local immune response to 
intranasal vaccines originates from the nasal associated lymphoid tissue (NALT) (72, 73). 
In addition, it is well known that respiratory tract offers a large surface area for aerosol 
targeting, including for vaccination. Alveolar space may be an ideal target for 
vaccination; this is due to its high permeability to macromolecules, as well as the 
adequate number of immunological cells. For example, delivery of (74) a polysaccharide 
vaccine into the alveoli region triggered a higher level of IgG antibody response than was 
observed in bronchial vaccination which targeted the upper airways. This maybe by 
virtue of the large surface area differences between the alveoli and bronchial regions, 
where the former is around 100 m
2
, while the latter is 1 m
2
. However, a later study failed 
to demonstrate the enhanced pulmonary response, leading to a further study of 
polysaccharide vaccine in the upper and lower airway (75, 76). Another research effort 
focusing on influenza vaccines and regional deposition differences in the lung indicated 
that deep lung immunization could achieve higher antibody level, in both local and serum 
(77).  A recent study highlighted the function of M cell role in the immune response in the 
upper respiratory tract. It was suggested that respiratory M cells were essential to trigger 
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the systemic and local immune responses (78).  
In the views of pulmonary vaccine development, we usually consider the 
following points: targeting specific cellular organs, enhancing delivery and achieving 
higher expression levels of antibody, and finding effective vaccine adjuvant with a 
promoting immune response. And a growing number of synthetic and natural polymers 
have been used as an adjuvant in pulmonary vaccine, since they can promote the uptake 
of antigens by antigen-presenting cells (APCs) (79). In the category of synthesis 
polymers, PLA (79, 80)and PGLA (81-83) are well studied examples. A recent study (84), 
which utilized the PLA and PLGA as adjuvants in the form nanoparticles, investigated the 
influence of surface charge, particle size, and surface hydrophobicity, on immune 
responses. And the results revealed that alveolar macrophages seemed to prefer 
phagocytosis of larger hydrophobic particles instead of smaller particles.  
In the category of natural polymers, chitosan has been well studied. It has been 
developed into many formulations for vaccination, including chitosan-based polymers, 
chitosan-based micro and nanoparticles, chitosan based formulations containing 
adjuvants, and chitosan-coated particles. For example, a recent report of a modified 
chitosan, N-Trimethyl chitosan (TMC), microparticles vaccine containing diphtheria 
toxoid was studied following pulmonary administration and showed detectable IgA and 
IgG levels (85). However, another study indicated an opposite response when using 
chitosan (86). When applied as adjuvant in adenovirus vaccine, chitosan reduced the 
immune responses in vivo via the negative impact on the CD8
+
 T cells. Thus, more 
research is needed for a clear mechanisms for chitosan specifically, and polymers in 
general, for pulmonary vaccination.  
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1.5 PHYSIOLOGICAL BARRIERS TO LUNG DELIVERY 
1.5.1 Aerodynamics 
There are still several physiological barriers that need to be considered when 
delivered the drug through the pulmonary route. The aerodynamic diameter of aerosol 
particles significantly influences the drug deposition and retention in different lung 
regions (87-89). The aerodynamic diameter is related to the geometric diameter and 
particle density (90, 91). 
The differences in aerodynamic size of particle results in differential deposition 
along various locations in the respiratory region. For example, particles with 
aerodynamic diameters bigger than 10 µm, will mostly deposit in the upper airway, 
including mouth, throat, and larynx. Particles with aerodynamic diameters lower than 
0.5μm, are often exhaled due to the short time given for deposition via diffusion of the 
particles in the alveoli region. Particles with aerodynamic diameters of 1-5μm can deposit 
in the alveolar region and are generally the target size for lung delivery for the diseases 
mentioned above (92, 93).  
Most research has focused on particles within size range of the 1-5μm for lung 
delivery, which is also referred as the “respirable” size range. One research trend over the 
past decade or so has been to develop large porous particles, that have a low density but 
large geometric size (45, 48, 59, 94).  For instance, via a double-emulsion method, PLGA 
microparticles were made with ammonium bicarbonate that is converted into ammonia 
and carbon dioxide gas, thus resulting in a highly-porous particle during particle 
formation. This type of porous particle could be applied for encapsulating both low 
molecular weight and macro molecules, such as doxorubicin·HCl and lysozyme. In the 
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case of doxorubicin, a sustained release profile was observed and 52% of drug was 
released over 4 days (59). Another example (48) showed the application of porous 
particle in an animal model. The author encapsulated the complex of prostaglandin E1 
(PGE1) and 2-hydroxypropyl-β- cyclodextrin (HP-β-CD) into a porous PLGA 
microparticle system. In this formulation, prostaglandin E1 (PGE1) was used to treat 
hypertension, while HPβCD, was selected as an osmotic agent to generate the pores in the 
particles surface. The in vivo results indicated that, this porous particle with a 
aerodynamic diameters of 1 to 5μm, exerted a prolonged release of PGE1 after 
intratracheal administration.  
1.5.2 Mucociliary clearance 
When deposited in the respiratory tract, drugs and drug carrying particles need to 
overcome efficient biological barriers before reaching the target site, whether is the 
epithelia or the blood circulation. 
Mucus barrier, which form part of the system that results in mucociliary 
clearance, is the first obstacle in the pulmonary delivery. Mucus layer mostly covers the 
airway epithelium which contains ciliated cells, secretory cells and basal cells. The 
mucus layer covering the conducing airways is about 5-10 μm thick (56, 95), and is 
mainly composed of mucins and glycoproteins (96). These two components contribute 
significantly to the binding ability of the mucus layer, in terms of electrostatic, 
hydrophobic, and hydrogen bonding interactions, which are all responsible for the 
trapping of drug or particles. There is a competition between the mucociliary clearance 
and dissolution followed by absorption. Dissolved material may cross the mucus layer by 
diffusion and reach the epithelial cell layer and thus avoid of mucociliary clearance. 
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While, the particles with slow dissolution or poor drug release (97, 98), are likely to be 
cleared via mucociliary clearance.  
The mucus layer functions as a physical, biochemical and immunological barrier. 
It may prevent the drug from reaching the epithelia, limiting its therapeutic effects. 
Therefore, avoidance of the mucociliary clearance attracted much attention among 
researchers. The first way is to disrupt the mucus layer with particles which could open 
new diffusion pathways via the interaction between the mucus and particle (44). 
Researchers (96) showed polystyrene particles and diesel particulate matter caused the 
disruption of mucus layer allowing increased drug permeation.  
Since mucus is adhesive, several researchers are developing mucoadhesive 
particles for lung delivery (99). It has been proposed that by utilizing the interaction 
between the mucus and particle, prolonged retention time of particles, may allow more 
drug diffusion through the mucus leading an increasing absorption and bioavailability (9).  
Polymers with mucoadhesive properties such as chitosan have been investigated. 
Chitosan exhibits bioadhesive properties that promote permeation, absorption of drug, as 
well as being a relatively biocompatible polymer (41, 100-105). 
 
 
1.5.3 Alveolar macrophages 
The clearance of particles which have reached the deep lung, specifically the 
lower alveolar region, occurs via the alveolar macrophages. Alveolar macrophages are 
abundant in the deep lung region, and more than 90% of these cells are located around 
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the alveolar septal junctional zones (106-108). On the surface of alveolar macrophages, 
many receptors exist, such as the immunoglobulin receptor (fcR), complement receptor 
(CR), mannose receptor (MR) and several types of scavenger receptors (106). In the 
cases of macromolecules, alveolar macrophages hinder the absorption to the lung 
circulation (109), because macromolecules are absorbed slowly and the prolonged 
transport process enables the alveolar macrophages to phagocytose the drug, thus 
reducing the bioavailability. Usually, the prolonged transportation happen in the 
molecules with molecular weight above 40 kDa (110). It seems that proteins with a lower 
molecular weight, approximately less than 25 kDa, were less influenced by alveolar 
macrophages (110, 111). For example, insulin (MW=5807) did not show a increase 
absorption even when the alveolar macrophages were disrupted (109, 111).  
Generally, alveolar macrophages efficiently engulf particles in the range 0.5-5 μm 
geometric size, which more or less overlaps with the respirable particle size range when 
particle density is one. Various strategies have been published for overcoming the uptake 
by alveolar macrophages. One approach is to form nanoparticles with geometric size less 
than 0.1μm (112, 113). Results showed that nanoparticles could escape the uptake by 
alveolar macrophages. In contrast to decreasing the particle size, another way is the 
development of large particles, which exhibit the large geometric size (more than 5 μm), 
but have low density, therefore performing like aerodynamically smaller respirable 
particles (45). The large geometric size of porous particles could reduce the clearance by 
alveolar macrophages (114, 115).  
Similarly swellable microparticles achieve aerodynamic properties allowing deep 
lung delivery but geometric properties that minimize macrophage uptake (54). This 
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formulation has respirable aerodynamic sizes when dry but large geometric sizes when 
swollen after being exposed to the moist lung epithelia lining fluid. Such characteristic 
enables this formulation evade macrophage uptake and show a sustained release profile 
through a controlled polymeric architecture. 
1.5.4 Drug absorption rates 
Generally, there are two types of epithelial cells in the respiratory system, and 
they are airway and alveolar epithelium (41), respectively. The airway epithelium mainly 
located at the upper/central respiratory tract. For the drug deposited in these regions, 
before being absorbed into the circulation of lung, they have to overcome two barriers, 
which are the thick mucus layer covering on the surface and the tight junctions between 
the epithelial cells. And the airway epithelial cells form a layer which is about 80 μm in 
the trachea region and decreases to around 10 μm in the region of bronchioles (110, 116). 
Besides the airway epithelium, micro-fold cells (M-cells) are found. M-cells are response 
for the uptake and transport of antigens within the mucosa-associated lymphoid tissue, 
leading to the immune activity in the upper respiratory tract (41, 117-119). In a recent 
study, the author delivered an antigen intranasally to mice, and found that M cells could 
take up the antigen and induct the immune responses, which was nasopharynx associated 
lymphoid tissue independent process (78). 
Alveolar epithelial cells are found in the distal respiratory tract. In the alveolar 
region, the mucus layer is replaced by the pulmonary surfactant, its thickness is around 
0.07 μm (110, 116). And the alveolar epithelial cells are composed of type I and II 
pneumocytes. Type I cells covers about 95% of the alveolar surface (120, 121), and form 
a thin layer of 0.05 µm thickness. And there is gap of around 1 nm between type I cells 
19 
 
(122). Type II cells are mainly in responsible for the release of surfactant. Compared with 
the 0.25 m
2
 area formed by the airway epithelium cells, the surface area in the alveolar 
region is about 70-100 m
2 
(121, 123, 124). 
In the alveolar region, epithelial cells form a much tighter barrier toward the 
absorption of the compounds than the pulmonary capillary endothelium (116, 122). For 
hydrophilic agents with lower molecular weight, they usually can be absorbed in the 
bloodstream within minutes (125-127), and are considered to be transported through 
transcellular diffusion (107, 116). However, if molecules that are insoluble due to the 
high hydrophobicity, it may take weeks for them to be absorbed (128). 
Hydrophilic molecules may be absorbed either via the transporters or through the 
tight junctions (107, 116). If the hydrophilic molecules exhibit neutral or negative charge 
and a small molecular weight, generally, they will be absorbed quickly within  60 min 
(107, 128). 
Even though it is still not clear which route is response for insulin absorption, the 
popular idea is via paracellular diffusion (107, 116). In addition, scientists suggest that 
the absorption of insulin or small peptides occurs at the distal airways just before the 
alveoli, since, with respect to the electrical resistance, the tight junctions at the distal 
airway are the lower than that of the trachea and alveolar region (107, 129). Furthermore, 
it appears that the number of tight junctions in upper airways are as much as five times 
higher than that in alveolar region (107, 116). Therefore, the ideal place for absorption of 
small peptides is the deep lungs (107, 125). 
The bottleneck for the absorption of macromolecules is the size (107). In a study 
investigating the permeability of dextran across the alveolar epithelium, the author 
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assessed the transport of dextran with different molecular weights (130). There was an 
inverse relationship between the permeability coefficient and molecular weight as 
expected. If the molecular weight of dextran was within the range of 4-40 kDa, in which 
the molecule had a radius of less than 5 nm, it seems that dextrans were transported 
through the epithelium via paracellular diffusion. While, the dextrans with the molecular 
weight between 70 kDa and 150 kDa, having a radius greater than 6nm, likely adopted 
other pathways to cross the epithelia, such as pinocytosis. 
In addition, receptor-mediated transcytosis or others, may be responsible for the 
transport of macromolecules and do not have apparent size-dependent transportation 
across the epithelium (121, 131). For example, there is still controversy in the transport of 
albumin. One accepted point is that the absorption of albumin was mediated through a 
specific binding protein expressed in the alveoli region (121, 132, 133).  
1.6 SUMMARY 
The lung is an excellent organ for the administration of a number of therapeutic 
agents due to the unique of method access to the lung tissue and the underlying rich blood 
supply. However, as evidenced by the discussion above, the lung poses significant 
challenges to drug delivery both anatomically and physiologically. Although a number of 
successful products have been developed and have had great impact on health care of 
millions, the next generation of inhaled therapeutics will have to achieve improved 
navigation through the complex cellular and molecular barriers recently elucidated within 
the lung. In the following chapters we will discuss how polymeric delivery systems are 
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A significant number of researchers have focused on pulmonary delivery as an 
alternative administration route owing to no first pass metabolism, low protease, thin 
epithelium barrier and large surface area in the lung system. Controlled release in the 
pulmonary delivery system further reduces loading dose, loading frequency and systemic 
side effects, and also increases duration of action and patient compliance. Compared to 
other microparticles used in controlled release pulmonary administration, hydrogels, the 
three dimensional polymeric matrix networks, were recently investigated as a result of 
particular swelling and mucoadhesive properties which could help pass pulmonary 
delivery barriers. This review herein first introduces the controlled release drug delivery 
to the lung, followed by the summary of currently available approaches for controlled 
release pulmonary drug delivery. Lastly, the origin, advantages, detailed applications and 
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2.2 INTRODUCTION OF CONTROLLED RELEASE DRUG DELIVERY TO 
THE LUNG 
Pulmonary delivery is to deliver drug particles directly to the lung through 
respiratory system. Due to advantages of large surface area for absorption, high 
permeability and no first pass metabolism, there are a variety of inhaled aerosols 
currently marketed for respiratory inflammation (1), cystic fibrosis (2), other lung 
disorders and several in development for rapid, noninvasive, systemic delivery of 
therapeutic agents. Challenges for pulmonary delivery also exist besides the advantages. 
Inhaled particles must first deposit into the respiratory systems for the therapeutic effects 
to occur. Large numbers of factors contribute to particle deposition, including particle 
size, shape and density, airflow velocity and volume, and the duration between 
inspiration and expiration. Associated with these factors, the mechanisms governing 
aerosol particle deposition within the airways are inertial impaction, sedimentation, 
diffusion and interception (3); while inertial impaction, sedimentation and diffusion are 
the major mechanisms. Once inhaled, particles firstly deposit on the mucosa covered by 
lung lining fluid. Particles soluble in the mucosal matrix will rapidly diffuse into the 
epithelial lining fluid and become available for absorption at different rates depending on 
their physicochemical properties.  However, poorly soluble drugs and drugs deposited as 
particulate materials have to dissolve before absorption and may undergo natural 
clearance caused by mucociliary escalator, cough, and/or alveolar macrophage 
phagocytosis. Insoluble or slowly dissolving particles deposited in the conducting 
airways are eliminated primarily by the mucociliary clearance, while particles that are 
small enough to deposit in the alveolar region are likely to be phagocytosed by alveolar 
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macrophages.  These deposition obstacles and clearance mechanisms yield short particle 
residence times in the airways and therefore resultant clinical/pharmacological effects are 
often much abbreviated requiring most aerosol medications to be administered multiple 
times daily.  
In addition to the convenience of once a day dosing, controlled release pulmonary 
drug delivery has numerous potential advantages, including reduced side effects, 
increased duration of action and improved compliance as well as potential cost savings. 
Controlled release formulations may allow patients with chronic diseases such as asthma 
to take treatments less frequently, without compromising the amount of drug patients are 
required to take into the lung. Recent efforts by companies such as Theravance and 
GlaxoSmithKline for example, indicate the strong desire to allow once a day dosing with 
similar clinical outcomes to current therapies (4). In addition, controlled formulations can 
moderate the drug peaks as to reduce toxicity which is common issue for some immediate 
release formulations containing drugs of narrow therapeutic indices, since the latter is 
often reported to cause toxicity and reduced efficacy. Another advantage of controlled 
delivery systems is evident by controlling delivery of two or more therapeutic agents 
from a single particle system to the lung. Consequently, a high possibility of increased 
synergism and additive effects can be observed. Many agents currently delivered to the 
airways are short acting, have short plasma half-lives, and thus are potential candidates 
for controlled release pulmonary delivery (5, 6). In recent years, controlled pulmonary 
delivery system has been so far unexploited but it is becoming increasingly attractive. 
Notably, there are no controlled release delivery pulmonary formulations currently on the 
market, although this field has been of interest to researchers for decades. Therefore, 
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development of sustained, modified, or controlled release therapeutic agents using 
biodegradable and biocompatible polymers would be beneficial for both local and 
systematic inhalation therapies.  
2.3 BRIEF SUMMARY OF APPROACHES USED TO DATE FOR 
CONTROLLED RELEASE PULMONARY DRUG DELIVERY 
Suitable inhaled carriers for controlled release pulmonary drug delivery should 
possess adequate aerodynamic properties, drug release, biodegradation and evasion of 
lung clearance mechanisms including mucociliary escalator and macrophage uptake. 
There have been a variety of carriers investigated, such as liposomes, biodegradable 
polymeric microspheres (MS), bioresponsive carriers, prodrugs, co-precipitates and 
hydrogels amongst others (7). Table 1 summarizes characteristics of commonly studied 
carriers for controlled release pulmonary drug delivery.  
2.3.1 Liposomes 
Liposomes are self-assembling lipid bilayers, with hydrophobic inner layer and 
hydrophilic outer layer. Liposomes can be prepared with a range of size and layers and 
will encapsulate both hydrophobic and hydrophilic drugs (27-32). Loading doses, drug 
release dynamics from the liposomes, and membrane properties can be adjusted by 
changing the compositions and ratio of various lipids (33). The percentage of drug 
entrapped in the liposomes, as an example, ranges from 55% to 80% and may even reach 
90% with different ratio of lipids (6, 12, 13, 34). Liposomes have been the most 
commonly used and investigated vehicles for controlled release of drugs for pulmonary 
delivery due to their biocompatibility, safety profile, and ability to avoid induction of an 
42 
 
immune response. Some liposomal pulmonary products have also progressed into 
advanced animal studies or clinical studies in humans (32, 33, 35). 
Liposomal dry powder inhaler formulations typically are prepared by lyophilization 
from liposome suspensions using different kinds of cryoprotecants in various mass ratios 
(e.g. sucrose, sorbolac, glutose, mannitol, trehalose or lactose). The function of 
cryoprotecants is to preserve the structural and functional integrity of liposomes during 
freeze drying process. But drug encapsulation efficiency after dehydration-rehydration 
generally will decrease depending on the cryoprotecant type and concentration used(6, 8). 
The lyophilization process normally takes days and is therefore not cost effective in many 
cases. The resulting porous cake after lyophilization have to be crushed by ball or jet 
milling mechanically and/or sieved through #120, #240 or #400-mesh manually, 
generating irregular and cohesive micron particles with poor flow. The flowability of dry 
powders is an important factor that influences the in vitro deposition performance. The 
liposomes subjected to lyophilization, milling and sieving therefore need to be mixed 
with coarse lactose carriers 63-106 µm sieved alpha-lactose monohydrate) to achieve 
higher fine particle deposition and correspondingly higher fine particle fraction (FPF) for 
inhalation delivery (6, 9).  
One step spray drying is also available to incorporate drug encapsulated liposome 
suspensions into dry powder inhalers (14, 36). Even spray dried liposomes have narrow 
size distributions and relatively good flow behavior thus potentially significantly higher 
inhalation performance without micronization and further mixing with coarse lactose 
carriers(9, 12, 14), physicochemical characterization indicates that these liposomes are 
still porous light spherical particles .  Therefore, the limitations of liposomal dry powder 
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are low drug loading, large volume and poor stability whatever manufactures method 
used. Compared to commercial dry powder inhalers (e.g. Aerolizer and Handihaler), 
which require size 3 capsules, the liposomal dry powders are filled into size 2 capsules to 
provide equivalent strength of drugs due to large ratio of inert excipients,  cryoprotecants  
and carriers (6, 12, 14, 15). The physical stability of liposomal formulations may be the 
major obstacle for commercialization. The guidelines for pharmaceutical acceptable 
liposomal formulations is 1-2 years stability under room temperature with high drug 
retention and no significant change in particle shape and size, which may not be easy to 
satisfy for currently designed liposomal dry formulations (9, 14, 15).  
2.3.2 Biodegradable Polymeric Microparticles 
Biodegradable microspheres prepared from synthetic polymers have been studied 
extensively for various administration routes as the characteristics of microspheres allow 
for both targeted and sustained drug release. Likewise, scientists have researched the use 
of the synthetic polymers for the sustained release of drugs in the lung and have 
demonstrated several reasons for the polymers to be used in the lung: a) the compositions 
of the material are safe in humans for inhalation,; b) the release of therapeutics entrapped 
could be regulated by varying the monomer compositions, ranging from hours up to 
several weeks. c) continuous release profiles up to 7 days of drugs with various molecular 
weights (443 to 5 x 10
6 
Da) may be delivered; d) the particle clearance from phagocytosis 
in the deep lung could be decreased e.g. by addition of PEG to the polymer backbone); e) 
varying the  polymer content  changes surface properties and aid aerosolization efficiency 
to the deep lung; f) polymer can be used to generate  highly porous large microparticles 
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that avoid macrophage clearance without compromising high deposition of drugs 
throughout the lung (25, 37).  
For effective delivery of particles into the lung, physical properties of the particles 
are crucial, especially the particle size, with the optimal range of 1-5 µm. Microparticles 
ideal for inhalation are susceptible to rapid alveolar macrophage removal  from the 
lung(38). Typically, particles with aerodynamic diameter smaller than around 5 µm may 
be delivered to the deep lung. Larger microparticles (e.g. 5-20 µm in diameter) with low 
density may also be designed such that they have a smaller aerodynamic diameter (< 5 
µm) and circumvent phagocytosis by macrophage. These type of engineered large porous 
microparticles exhibit the aerodynamic size of smaller particles are not only suitable for 
deep lung delivery, but they also have geometric sizes large enough to resist alveolar 
macrophage uptake and subsequent clearance prior to drug release from the carrier 
vehicles (16, 39).  
2.3.3 Bioresponsive drug delivery systems 
Apart from conventional diffusion controlled release from polymeric delivery 
systems, bioresponsive drug delivery systems are attractive due to several potential 
advantages over traditional polymeric drug delivery systems. Drug release from 
polymeric delivery systems generally happens as the polymer degrades through 
nonspecific chemical reactions. Due to differences in physiological states and locations of 
disposition, these passive drug release mechanisms may result in inconsistent drug 
release profiles, significant intra and inter-patient variability, and poor response to 
physiological changes in the body (40). While a number of the bioresponsive systems 
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have been investigated for oral or even parenteral delivery, few literature reports exist for 
these systems applied to inhalation and the lung (40, 41).  
2.3.4 Hydrogels 
Hydrogels, the three-dimensional, polymeric matrix networks (42), are composed 
of water-soluble natural or synthetic polymers, which are cross-linked and absorb a large 
amount of water into the developed network structure (42, 43). Many hydrogels have 
these properties and are closely related in terms of physicochemistry to endogenous 
extracellular matrix present throughout the body. Due to these advantages, hydrogels 
have been used in many clinical investigations, such as tissue engineering, cellular 
immobilization, separation of biomolecules or cells, as well as drug delivery (44). In the 
case of drug delivery, hydrogels are regarded as a potentially ideal delivery system, given 
their generally high biocompatibility to living tissues with respect to its physical 
properties, biodegradability, low toxicity, high water content, and low interfacial tension 
(43). The low interfacial tension with the surrounding biological environment minimizes 
protein adsorption and adhesion. As a consequence, low adverse interactions of the gel 
surface with the aqueous biological environment are observed. These observations were 
first established over 50 years ago (2). In addition, hydrogels are capable of incorporating 
a variety of molecules for optimized controlled-release profiles, which are controlled by 
adjusting polymer structure, degree of crosslinking and polymer ratios (42, 43).  
Furthermore, controlled drug release hydrogels responsive to external stimulus (e.g. 
the pH value (45, 46), local tissue temperature (47, 48), electric field (47, 49), magnetic 
field(50-52), and specific disease-related enzymes (53, 54) are developed. These external 
conditions can be used as triggers to more specifically control drug release in a “smart” 
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manner. These bio-responsiveness switches drug release on and off according to spatial 
or temporal requirements of the drug, thus reducing the frequency of drug administration 
and the side effects due to off-targeting and  undesired body distribution (55, 56).  
Given the need to develop controlled drug release systems for pulmonary delivery 
(57, 58), hydrogel systems have recently been the subject of several investigations 
reported in the literature. A variety of molecules, such as antibiotics (44), antibodies (59), 
antitumor agents (60), nanoparticles (61), and even magnetic particles (62), have recently 
been incorporated into hydrogel systems for direct lung administration. However, in 
contrast to other routes of administration, studies of hydrogels for pulmonary delivery are 
less common and are more frequently investigated in oral dosage forms.  
With so many carriers systems available for controlled release pulmonary delivery, 
the focus of this review however is the utilization of hydrogel based systems for 
pulmonary drug delivery.    
2.4 ADVANTAGES OF HYDROGEL-BASED SYSTEM FOR PULMONARY 
DRUG DELIVERY 
In the respiratory system, the conducting airway is covered with a relatively thick 
layer (5 - 10 µm) of mucus (63, 64), which exhibits specific surface characteristics (such 
as wettability and adhesivity) to trap exogenous particulates that have been inhaled (65). 
This mucoadhesive nature endows a direct physical interaction between a solid surface 
(i.e. inhaled particle containing drug) and mucus layer. The close interaction may 
significantly increase the bioavailability of a drug due to the longer residence time of 
drug formulation in the respiratory system, especially if the formulation is made of 
hydrogel particles which have particular mucoadhesive properties. The increased 
47 
 
contacting time between hydrogel formulation and mucus layer permits a prolonged 
period for the penetration of drug formulation into mucus layer, thus leading to a 
potentially higher absorption of drug.  
Given that higher bioavailability of drug may be achieved due to mucoadhesive 
interactions between drug formulation surfaces and mucus layer as shown most 
extensively in the oral dosage form literature, the development of mucoadhesive systems 
for pulmonary delivery has been postulated as a potential advantageous method of 
sustaining drug release. However, as the literature has reported that mucoadhesive 
particles might inhibit the mucociliary clearance via increasing the viscoelastic properties 
of the mucosal fluids, there is a deep concern for the time period of mucus renewal and 
side effects of inhibiting mucociliary clearance (66). In addition to mucociliary clearance, 
another important clearance mechanism in airway is the rapid macrophage uptake of 
inhaled particulates (59, 67-69). For macrophage uptake, the preferred geometric size 
range of particles is overlapped with most respirable aerodynamic size range of 0.5 µm – 
5 µm (70, 71). The size issue results in the rapid phagocytosis of drug delivery particles 
and subsequent loss of pharmacological effect of the therapeutic agents. To address this 
matter, several approaches have been studied. For example, respirable porous large 
particles were developed with a larger geometric size (>6µm) as to be beyond the 
preferred size for macrophage uptake (72-74). Also, there is some evidence that nano-
sized particles may effectively evade the macrophage uptake in the alveolar region, 
because the particles are too small to be recognized by macrophages (75, 76). However, 
the particles smaller than 0.5 micron, without a prolonged breath hold, are exhaled out of 
airway (77-80). If nanoparticles are inhaled as microsized aggregates/agglomerates due to 
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higher cohesive force, nanoparticle deposition in the lung may occur (70, 81, 82).  The 
third method is to fabricate the polymeric hydrogels with dry state. The dried state 
hydrogels have proper respirable aerodynamic sizes to locate into the deep lung where 
effective absorption occurs, while swell to large geometric sizes upon exposed to the 
moist lung epithelia lining fluid, thus prevented from macrophage uptake (83, 84). 
Hydrogel particle residence time can be increased in the airways using two main 
methods: (1) within the conducting airways, or (2) avoidance of macrophage uptake in 
the deep lung. Particle adhesion to the mucus (mucoadhesion) has widely been exploited 
as a method to overcome the limitations imposed by mucociliary clearance, especially in 
the nasal cavity and GI tracts. Here, long polymer chains attached to the surface of 
particles may enable the particles to become intertwined and entangled with the mucus 
network. Because of this interaction, mucoadhesive particles typically exhibit slower 
particle transit time from the mucosal site, likely due to an increase in the viscoelastic 
properties of the mucosal fluid which inhibits the mucociliary clearance. The ability of 
mucoadheisve particles to limit clearance in vivo has been indirectly measured in a few 
cases in the airways (85-87). However, the potential limitations to this strategy include 
the time scale for mucus renewal and concern over potential negative effects of inhibiting 
mucociliary clearance.  
Avoidance of macrophage uptake in the non-ciliated peripheral airways can be 
achieved chemically or physically. Chemically, highly hydrated polymers like 
polyethylene glycol can confer greater levels of stealth to foreign particles. This is well 
known and deployed heavily by the field of PEGylation. In the lung, the same principles 
apply. Physically, macrophage engulfment can also be delayed or avoided by ensuring 
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the particle size (of the swollen hydrogel) is too large for efficient pahgocytosis. 
Swellable particle avoidance of macrophage uptake is addressed below” 
Thus, recent reports have realized two significant properties of hydrogels that may 
be useful in overcoming some of the barriers of controlled pulmonary drug delivery: (1) 
the potential for achieving mucus adhesion and (2) the ability to control swelling 
behavior of the hydrogel particles. Hydrogels with enabled mucus-adhesive properties 
allow for a reduced clearance from the mucocilliary escalator, leading to longer residence 
time within the respiratory tract, and higher absorption rate into circular system (43, 88, 
89). Swelling, the basic property of hydrogels, can be controlled by the polymer type, 
crosslinking degree, and processing conditions of hydrogel particles (43, 90-93). 
Swelling of hydrogels will alter the physical (e.g. particle size distributions) and chemical 
characteristics (e.g. water content, surface tension) of hydrogels particles to evade 
alveolar macrophage uptake. 
2.5 EXPERIMENTAL APPLICATIONS OF HYDROGELS FOR CONTROLLED 
PULMONARY DELIVERY  
2.5.1 Hydrogel with synthetic polymers   
In general, synthetic hydrogels have been studied more often than natural hydrogels 
due to their well-defined molecular weight and designable modification. Also, the 
interaction between cells and these synthetic hydrogels are closely influenced by surface 
mechanical characterization of hydrogels (94-96). In a report (97), a copolymer hydrogel 
composed of 2-hydroxyethyl methacrylate (HEMA) and 2-methacryloxyethyl trimethyl 
ammonium chloride (MAETAC) was exploited to study the pulmonary artery endothelial 
cells attachment. Increasing proportions of positively charged MAETAC increased the 
50 
 
swollen states of hydrogel, as well as its positive charge on surface. Hydrogel with more 
positive charge promoted the pulmonary artery endothelial cells attachment. This result 
indicated that surface charge density of hydrogel is a critical factor for the binding 
interaction between hydrogel and cells, especially for the lung targeted delivery.  
Hydrogel-based polyacrylamide microparticles (PMP, 1-5 µM) and nanoparticles 
(PNP, <100 nm, diameter) was formed (98). These hydrogels were intratracheally 
administered to mice to investigate the lung retention, cell-uptake, and clearance. These 
investigations focused on interactions of the hydrogel particles of different size and 
surface modification with respiratory environment, epithelial and immune cells, and 
extrapulmonary organs. Results from the in vivo lung retention study showed that 
nanoparticles had better lung tissue location and retention than microparticles, and 
nanoparticles were mainly cleared via microphage uptake. . In addition, the author found 
that the clearance of microparticle, at one side, was accomplished by mucociliary activity, 
which was evident by the higher biodistribution than nanopartilces, especially in GI tract, 
such as stomach and intestine. Also, at the other side, microparticles would penetrate into 
the systemic circulation by transit through the alveolar epithelium-capillary endothelial 
barriers, which could be related to some unrecognized alteration or injury to the alveolar 
epithelial cell basement membrane as the author mentioned. In this study, the author 
investigated the effect of hydrogel’size on their fates in the animal study, showing that 
synthetic polymer-based hydrogel particles either in micro-size or nano-szie, could be 
untilized to provide higher local concentration of drug or imaging agents, limite systemic 




2.5.2 Hydrogel with natural polymers 
A novel Zn
2+
-cross-linked alginate microparticles for controlled pulmonary 
delivery of protein drugs was developed (99). The approach to fabricate microparticles 
was accomplished by one-step spray drying aqueous alginate solutions, containing the 
BSA, Zn(NH3)4SO4, and other additional excipients. Via spray drying, water and NH3 
were evaporated, leaving the free cations of Zn
2+
 to physically interact with the negative 
charged alginate chain.  
The in vitro release study was conducted to investigate the underlying protein 
release mechanism from this novel Zn
2+
-cross-linked alginate microparticles, as well as 
the influence of the type of releasing medium on protein release and physical structure of 
aliginate microparticles. The result showed that the model protein, BSA, had the slowest 
release profile from the particles composed of BSA, aliginate and Zn(NH3)4SO4, than that 
from the controlled groups, including particles pure BSA, particles of BSA and alginate, 
and particles of BSA and  Zn(NH3)4SO4. The appropriate explanation for the observed 
slowest release profile could be attributed to two barriers hindering the BSA release. 
Firstly, BSA should penetrate through tight hydrogel network formed by the Zn
2+ 
and 
alginate. Secondly, it was observed that a complex of znic and BSA was formed in this 
formulation, which indicates BSA also needs to get free from this complex before being 
released. Not only had the presence of Zn
2+
 in the cross-linked and protein complex 
influence the release profile, but the components and their concentrations in the release 
medium also largely affected the protein release with respect to the erosion of Zn
2+
 cross-
linked alginate networks. For example, 5-fold-diluted USP 34 phosphate buffer had a 
slower release than that of un-diluted buffer, since the latter had a higher concentration of 
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cations which will compete with Zn
2+ 
for the binding site in alginate chains. Additionally, 
white precipitate consisting of needle-shaped Zn
2+
(PO4)2 crystals observed in the release 
medium accelerated the erosion of alginate networks.  
Carrageenans, natural sulfate polysaccharides, have been formed into hydrogel and 
applied widely in biomedical research (100-104). This is because carrageenan hydrogel 
has the thermos-reversibility and appropriate viscoelastic properties. In its application of 
drug delivery systems, carrageenan hydrogel has been served as drug carriers for 
meloxicam (105), β-carotene (106), camptothecin (107) and ketoprofen (108). Even no 
carrageenan hydrogel was reported in pulmonary delivery till now; carrageenan had been 
exploited as a viscous vehicle on pulmonary absorption of antiasthmatic drugs, 
theophylline and fluticasone propionate (109). Pulmonary absorption of these two drugs 
was investigated in rats. In vivo results showed that, among the three classes of 
carrageenan, which are kappa, iota, and lambda, iota-carrageenan could significantly 
decrease the Cmax of theophylline, while increase its Tmax value. In case of kappa-
carrageenan, it could also regulate the pulmonary absorption of fluticasone propionate. 
These results revealed that carrageenan is an appropriate candidate for pulmonary 
formulation; its sub-components could even be utilized for controlling delivery of a 
certain drug.  
Gelatins are obtained from animal collagens by either acid hydrolysis (type A) or 
alkaline hydrolysis (type B). Because of the highly biocompatibility and, gelatin has been 
widely applied in pharmaceutical formulation, such as implantable delivery system as a 
biodegradable matrix materials (110), as well as hard or soft gelatin capsules (111, 112). 
In the application of pulmonary delivery, gelatin was formed as microsphere to deliver 
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salmon calcitonin (113). Two types of gelatin microspheres were formulated using the 
difference of isoelectric point between acidic gelatin (5.0) and basic gelatin at pH 7.0. 
Acidic gelatin expressing negative charge released 40% of salmon calcitonin within 2 h, 
which is much slower than that from the basic gelatin showing positive charge, because 
the positive charge formulation showed a cumulative release of almost 85% within same 
period.  Both of these two formulations were administered into rats via pulmonary route 
to investigate their bioactivity compared to pure drug in PBS solution. These in vivo 
studies revealed that positively charged gelatin microspheres with smaller size of 3.4µm 
appeared to have better effect than negatively charge gelatin formulation with a size 
around to 10 µm; however, in contrast to control group of pure drug in PBS solution, 
gelatin formulation indicated an improved and sustained bioactivity of salmon calcitonin. 
This study demonstrated the capability of gelatin to deliver drugs via pulmonary route in 
a controlled manner.     
Hyaluronic acid (HA) is a naturally occurred polymer which has been well studied 
in biomedical application due to its high biocompatibility and low immunogenicity (114-
117). In its application of pulmonary drug delivery, several advantages had been 
highlighted for utilizing HA as a drug carrier (113). Firstly, HA is endogenous to the 
pulmonary environment. In addition, it regulates the function of various inflammatory 
mediators. Finally, the bio-adhesive property allows HA formulation achieve a longer 
retention period in respiratory by avoiding the mucociliary clearance (113). Given these 
mentioned benefits, several non-hydrogel formulations composed of HA have been 
developed for delivery medicines to the lung, such as insulin (118) and fluticasone 
propionate (113). Studies showed that effective delivery manner of these therapeutic 
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agents was observed form these HA formulations which are not in HA hydrogel forms. 
Even though no HA hydrogel formulations designed specifically for pulmonary delivery 
have been investigated, HA hydrogels are well practiced approaches for drug delivery 
(116, 119-121), and its application of incorporating medications for lung delivery is a 
promising topic for investigation.  
The fate of hydrogels, either with synthetic polymers or natural polymers, such as 
carrageenans and gelatin, depends on the deposition site in the lung just the same as other 
particles. Generally, particles deposited in the conducting airway are cleared by the 
mucociliary escalator and then are transported to GI tract. Specifically, particles 
entrapped within the mucus and macrophages are carried up with mucociliary escalator to 
the pharynx for swallow.  
On the other hand, particles deposited in the alveolar region are phagocytosed by 
macrophages. These macrophages may arrive at the terminal bronchioles, also get access 
to mucociliay escalator, and then are cleared from the body. Other macrophages or 
inflammatory cells can carry the phagocytosed particles into the interstitial spaces. After 
entering into the interstitial space, the particles in the macrophages are transported to the 
regional lymph modes through the lymphatics or may go directly to the bloodstream. 
Besides, carrageenans and gelatin may be enzymatically degraded. Enzymes found 
in the intestinal-hepatic metabolism system are also observed in lungs but with lower 
level, therefore the drug-metabolizing capability of the lung is lower than that of the liver. 
In addition, there is a possibility that these exogenous components can trigger the 
inflammatory response in the lungs.   
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2.5.3 Hydrogel in a nanoparticle-in-microgel form 
Recently, an innovative nanoparticle-in-microgel system was development for 
pulmonary delivery (59). This unique system simply composed of a multi-armed poly 
(ethylene glycol) crossed linked with trypsin sensitive peptide. The cross-linking reaction 
was achieved through a newly developed method, involving a Michael addition during 
(water-in-oil) emulsion (MADE). With only one additional procedure of mixing, this 
fabricated microgel system could incorporate nanoparticles with a wide size range of 
20nm to 200nm, and also encapsulated some biological agents, such as IgG and DNA as 
examples. This microgel was investigated with the aim of overcoming the critical 
challenges for pulmonary delivery, including efficient deep lung delivery, avoiding rapid 
clearance by macrophages, as well as disease-specific triggered release.  Effective 
delivery of inhalable particles to deep lung region requires that the aerodynamic diameter 
of particle should be in the range of 0.5-5 µm (83, 122). The normalized theoretical 
aerodynamic diameter over the entire population for these microgel particles was about 
4.809 µm, allowing sufficient deep lung delivery. The aerodynamic diameter of inhalable 
particles was calculated based on its geometric diameter, which was about 4.694 µm in 
this case. After 24 hrs of swelling, the geometric size of microgel was larger than 6 µm, 
which is beyond the preferred size for rapid macrophage uptake. However, the period for 
the uptake of micro-sized particles by macrophage is within mins (123-125), 24 hrs is 
obvious longer for the microgel to avoid the uptake. Nonetheless, the microgel developed 
in this study which was freshly made (pre-swelling) could effectively avoid macrophage 
uptake at both 2 and 24 h. This interesting phenomenon could partially attribute to the 
hydrophilic materials, swelling behavior, as well as PEG composition. After avoiding 
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macrophages uptake, microgel would rapidly release its biologics or nanoparticles in the 
presence of specific enzyme under a disease-responsive drug release mechanism. This 
disease–stimuli release manner could largely improve the drug potency and targeting 
efficiency, while reducing side effects because of non-uniform distribution in the 
respiratory system.   
2.5.4 Dried swellable hydrogel particles 
Acknowledging the current barriers to successful pulmonary delivery, various 
approaches have been reported in literatures as to improve the deep lung targeting, to 
avoid the efficient clearance, as well as to achieve a sustained/controlled release profile. 
These approaches in terms of formulations could be summarized as nanoparticles, 
microencapsulated particles, PEGylated drugs, large porous particles, and micro/nano-
microparticles systems. Our group has consistently focused on the development of dried 
swellable hydrogel particles (60, 83, 84, 126). We proposed that formulations typically 
designed for pulmonary drug delivery should exhibit the characterization of dried 
hydrogel drug carriers, which have respirable aerodynamic size and escape from uptaking 
by macrophases, in addition to showing desirable controlled release kinetics. These dried 
hydrogel carrier systems were successfully developed, which, in the dehydrated state, 
exhibit appropriate aerodynamic profile for delivering to deep lung region; after 
deposition in the hydrated respiratory tract, the dried hydrogels gradually swell to a larger 
size within minutes, thus leading to evade macrophage uptake and release of 
encapsulated therapeutic agents, either nanoparticles or molecules in the swelled particles 
(61, 126).  One of recent formulations exploited in our lab is to incorporate drug-loaded 
nanoparticles into swellable/respirable microparticles, with the aim of achieving a 
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sustained drug release (126). This nano-in-microparticles formulation would release the 
majority drug under a controlled manner in the  target region where the uptake of micro-
size particles by macrophages takes place. In this work, the target region was the alveolar 
region.  Additionally, the nanoparticles fully encapsulated into the microparticles matrix 
would not be exhaled from the lung after inspiration. The encapsulated nanoparticles 
were first fabricated using poly (D, L-lactic-co-glycolic acid) (PLGA) to load curcumin, 
with a modified single emulsion-solvent evaporation method. Then, the drug-loaded 
nanoparticles were added into the solution of PEGylated Chitosan to form a 
homogeneous mixture, which were spray dried to obtain the respirable/swellable 
hydrogel microspheres. After a series of in vitro characterizations, the average particle 
geometric size for drug- loaded PLGA nanoparticles and hydrogel microspheres 
encapsulating the drug-loaded PLGA nanoparticles were around 230 nm and 3.5 µm, 
respectively. Prepared formulations showed a fast initial swelling within the first few 
minutes. For example, the diameter of particles had increased from about 3−3.5 μm when 
dry to 35 µm after 6 min of swelling. This swelling continued regularly with time to 
reach 80 µm at 20 min. To avoid macrophage clearance, microparticles must typically 
have a diameter >6 µm. In addition, the mass median aerodynamic diameters (MMAD, 
µm) of the inhalable hydrogel microspheres were in the range of 1.25-1.96 µm. This 
hydrogel with ideal aerodynamic diameter showed two phase of drug release in the in 
vitro test. Initially, 20% of curcumin was released within the first hour, which followed 
with a slow release manner of releasing 45% of drug by 24 hrs. The fast initial release 
was largely contributed to the swollen of hydrogel upon interacting with release medium 
during the first 1 hr.   
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2.6 CONSIDERATION OF THERAPEUTIC DOSAGE FOR CONTROLLED 
PULMONARY DELIVERY 
Compared to immediate release formulation, controlled release formulations are 
generally designed to contain multiple doses, which provides therapeutic effects over a 
longer period with fewer administration frequency. In addition, controlled release 
formulations for inhalation are becoming increasingly attractive due to the advantages of 
respiratory systems for the local and systemic drug delivery. However, till now there is 
no controlled release inhalation dosage form approved in the USA. The absence of which 
may be the result of the untested long-term safety profile of many of the excipients that 
could be potentially used (127-129). 
Generally, it is the excipients which control and contribute the most to the 
prolonged drug release. Thus, a large mass fraction of excipients in the sustained release 
dosage from may be administered daily through inhalation pathway. Furthermore, the 
excipients used in controlled dosage forms are often polymers, either from natural or 
synthetic resources. However, few polymers are in approved inhalation products.  
Therefore, the usage of un-approved excipients in the controlled release formulation for 
inhalation will require extensive toxicity testing.  
One important consideration in the development of controlled or sustained release 
formulations in pulmonary drug delivery is the dose. Because at least a 24 hour dose 
might seem a basic requirement for these systems one must consider the mass of drug 
required to be loaded into the delivery system to maintain therapeutic levels during this 
period. In addition, the mass of the delivery system must also be considered because there 
appear to be limits on the total mass of aerosol that can be administered. Typical DPIs 
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deliver between 18 and 550 µg of active drug per dose (130). In addition, there is 
signficant clinical experience with larger powder doses to the airways. The recommended 
dose of Bronchitol, for example is 400 mg. This requires the inhalation of the contents of 
ten capsules via the inhaler device. Also, the Tobi(R) Podhaler (TM), delivers 112 mg of 
powder to the airways using four 28 mg inhalations. Therefore if one can estimate the 
order of magnitude limits of drug loading in the sustained release matrix as being as 
approximately 1% w/w in dry powder systems. If however, large payloads of drug are 
required to be delivered, as in the case of antibiotics in the treatment of lung infections, 
much higher drug loadings will be required, or the order of 50% or more.  
2.7 FUTURE PERSPECTIVE 
Intensive studies in hydrogels have contributed our present understanding of this 
unique delivery formulation. Due to its properties, such as mucoadheisive and swellable, 
hydrogel seems to be a promising strategy for pulmonary drug delivery. In addition, a 
large number of therapeutic agents, including small molecules, peptides, and protein, 
even gene, could be incorporated into the polymeric matrix of hydrogel, which 
significantly enlarged the scope of disease treated via respiratory delivery. Moreover, the 
controlled release manner of these therapeutic agents, as well as their specific site 
targeting, largely reduced the side effects and administration frequency. However, a huge 
gap between the experimental data and clinical reality still exists due to critical 
challenges in terms of the physiological variations within different respiratory diseases, 
location of deep lung, less immunological response, and long term usage safety. 
Therefore, further studies of both experimental and clinical aspects have to be explored to 
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Chapter 3: Research objective 
Recently, the use of inhalation aerosols to treat the Cystic Fibrosis directly has 
improved treatment and reduced side effects. However, even the obvious advantages of 
aerosols over systemic therapy, current inhaled medications for Cystic Fibrosis are still 
inefficient, time consuming. Plus, most of Cystic Fibrosis patients exhibit reduced airway 
diameters due to inflammation, increased mucus production, frequently infection, and 
combinations of these states. Those properties of Cystic Fibrosis directly lead to the 
inefficient or even fail of most aerosolization. Therefore, the design of efficient drug 
delivery should consider the physiological changes, such as airway obstruction, kinetics 
of drug diffusion through mucus, drug release and excipients degradation in the 
inflammatory environment. The objective of this proposal is to evaluate the delivery 
properties of aerosol particles which are easily formed, to overcome the physiological 
barriers in Cystic Fibrosis.  
Our first hypothesis is that ciprofloxacin can play a role of cross-linker, similar 
with Calcium, to form hydrogel with alginate which is a natural biodegradable polymer. 
Furthermore, this novel and easily formed hydrogel can release the drug in a sustained 
release profile, which is preferred in treatment of Cystic Fibrosis.  In the proposal study, 
we will utilize the antibiotics, ciprofloxacin to cross-link the alginate to finally form a 
hydrogel, which also entraps free ciprofloxacin. We also will evaluate its aerodynamic 
performance suitable for aerosolization. Through cell based assay, to test its swelling 
properties, which allow delayed macrophage uptake. Moreover, we will evaluate this 
swellable hydrogel in an animal model to demonstrate its sustained release property.   
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In a recent formulation investigated in our laboratory, a copolymer of PEG grafted 
onto phthaloyl chitosan (PEG-g-PHCs) self-assembled nanoparticles were entrapped into 
Ca
2+
 cross-linked alginate to prepare respirable microparticles with semi-interpenetrating 
polymer networks (semi-IPN particles) for pulmonary sustained drug delivery. In 
Chapter 4, a nano-in-micro hydrogel particle formulation was developed for sustained 
pulmonary drug delivery, which takes the advantages of both nanoparticles and swellable 
and respirable hydrogel particles.  The dry nano-in-micro hydrogel particles exhibited a 
rapid initial swelling within 2 minutes, and showed sustained drug release. Preliminary in 
vivo pharmacokinetic studies were performed with formulations delivered to rats by 
intratracheal insufflation. Ciprofloxacin concentrations in plasma and in lung tissue and 
lavage were measured up to 7 hr. The swellable particles showed a lower ciprofloxacin 
levels in plasma than the controlled group (a mixture of lactose with micronized 
ciprofloxacin); while swellable particles achieved higher concentrations in lung tissue 
and lavage, indicating the swellable particles could be used for controlling drug release 
and prolonging lung drug concentrations 
In the chapter 4, we had reported that ciprofloxacin can function as a cross-linker to 
interact with alginate to form hydrogel. Based on this interaction and the fact of the 
complex and costly process of making PEGylated chitosan, we therefore directly 
combined ciprofloxacin with alginate to form hydrogel dry powder, without the addition 
of extra chitosan in Chapter 5. In such way, we simplified the preparation method for 
hydrogel particles, decreased the potential risk of polymeric chitosan to the lung tissue, 
and increased the ciprofloxacin loading efficiency from 30% to 50% in the finial 
microsized hydrogel dry powder.  The alginate hydrogel dry powder system exhibited 
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high ciprofloxacin loading (57%) and a geometric size of less than 5 µm. Ciprofloxacin 
was present in the amorphous state in the dry powder and was released in a controlled 
release manner relative to ciprofloxacin alone, i.e. 80% of drug released at 8 hours. The 
hydrogel dry powder also achieved a high fine particle fraction (above 45%) as 
determined by the in vitro aerosol performance study. A novel inhalable alginate 
hydrogel dry powder system was successfully formed and it indicated broader 
applications of other antibiotics for the treatment of lung infections. 
Our second hypothesis, derived from the proposed mechanisms of biofilm 
resistances, is that reducing the binding or affinity of the antibacterial toward the biofilm 
itself will result in improved antibiotic efficacy.  To test this hypothesis, in Chapter 6, a 
conventional antibiotic, tobramycin was chemically modified. Tobramycin has previously 
been demonstrated to bind to biofilm matrices, thus reducing the effective concentration 
of antimicrobial able to reach the pathogenic organisms, as well as limiting the 
penetration of the antibacterial agent to the deeper microstructure of the biofilm, thereby 
creating an undesirable stress response in the pathogen. It is essential to improve the 
penetrative capabilities of existing antimicrobials, such as tobramycin, in order to 
overcome thick biofilm barriers and to achieve superior elimination of P. aeruginosa 
biofilms. Modifying existing drugs by conjugating them to polymers has been widely 
reported to improve the efficacy of existing drugs. Predominantly, conjugation to 
polyethylene glycol (PEG) has been used to increase plasma half-lives of therapeutic 
agents. PEGylation has also been shown to improve diffusion of nanoparticles through 
mucus. To our knowledge, the conjugation of PEG to tobramycin has not been reported 
in the literature, but its feasibility is supported by reports that have shown that chemical 
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modification at the 6’ amine group of tobramycin will still maintain antibacterial activity. 
The minimum inhibitory concentration (MIC80) of Tob-PEG was higher (13.9 µmol/L) 
than that of tobramycin (1.4 µmol/L) in the planktonic phases. In contrast, the Tob-PEG 
was approximately 3.2 fold more effective in eliminating bacterial biofilms than 
tobramycin. Specifically, Tob-PEG had MIC80 lower than those exhibited by tobramycin 
(27.8 µmol/L vs 89.8 µmol/L). Confocal laser scanning microscope and scanning 
electron microscope findings further confirmed these data.  Thus, modification of 
antimicrobial as by PEGylation appears to be a promising approach for overcoming the 










Chapter 4: Swellable ciprofloxacin-loaded nano-in-micro hydrogel 




Incorporation of drug-loaded nanoparticles into swellable and respirable micro 
particles is a promising strategy to avoid rapid clearance from the lung and achieve 
sustained drug release. In this investigation, a co-polymer of Polyethylene glycol grafted 
onto phthaloyl chitosan (PEG-g-PHCs) was synthesized, and then self-assembled with 
ciprofloxacin to form drug-loaded nanoparticles. The nanoparticles and free drug were 
encapsulated into respirable and swellable alginate micro hydrogel particles and assessed 
as a novel system for pulmonary sustained drug delivery. Particle size, morphology, 
dynamic swelling profile and in vitro drug release were investigated. Results showed that 
drug-loaded nanoparticles with size of 218 nm were entrapped into 3.9 µm micro 
hydrogel particles. The dry nano-in-micro hydrogel particles exhibited a rapid initial 
swelling within 2 minutes, and showed sustained drug release. Preliminary in vivo 
pharmacokinetic studies were performed with formulations delivered to rats by 
intratracheal insufflation. Ciprofloxacin concentrations in plasma and in lung tissue and 
lavage were measured up to 7 hr.  
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The swellable particles showed a lower ciprofloxacin levels in plasma than the controlled 
group (a mixture of lactose with micronized ciprofloxacin); while swellable particles 
achieved higher concentrations in lung tissue and lavage, indicating the swellable 
particles could be used for controlling drug release and prolonging lung drug 





Delivering antibiotics through the pulmonary route increases the local drug 
concentration in the lung, leading to improved local antibacterial effect in lung infections 
(1, 2). In patients with lung infections, such as cystic fibrosis and pneumonia, the 
reduction of administration frequency (3), dose (4) and duration of inhalation treatment 
(5) will increase the patient’s compliance and adherence to the therapy (6). The 
administration frequency of inhalation aerosols could be reduced by prolonging the 
residence time of drug-releasing particles in the lung, essentially by using a sustained 
release formulation (7). However, there are few effective sustained release pulmonary 
formulations developed currently because of the efficient clearance of inhaled particles 
either by mucociliary escalator (8) or alveolar macrophage uptake (9).  
For effective delivery of sustained release formulations into the lung, drug-loaded 
particles should have suitable aerodynamic properties, which is primarily determined 
either by the particle size, shape and particle density. The preferred aerodynamic particle 
size range for deep lung delivery is around 0.5-5µm (9). However, the conundrum is that 
particles within this size range are subject to rapid phagocytosis and are cleared by 
alveolar macrophages (10, 11). To overcome the  clearance due to alveolar macrophage 
uptake, two main approaches, larger particles with low density (12) and nanoparticles 
(13, 14), have been explored. Low density particles with larger micro-size (i.e. greater 
than around 6 microns) have been shown to reduce the uptake rate by macrophages. 
However, there may be limitations of controlling the drug release from this type of 
particle system (15). Even though nanoparticles have shown promise in evading 
phagocytosis and mucociliary clearance, they may be exhaled easily following inhalation 
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resulting in lower deposition in the airways (16, 17). Additionally, it is critical that 
nanoparticles must not tend to aggregate together, forming microparticles which once 
again lead to rapid clearance by macrophages (15, 18).  
Thus, it would be extremely useful to develop an alternative pulmonary delivery 
vector for increasing the residence time of the drugs in the lung. Such a delivery vector 
should have efficient deposition in the deep lung and diminish alveolar macrophage 
uptake. Acknowledging the physiological barriers to successful pulmonary drug delivery 
of controlled release systems, our group has worked on a third approach for improving 
prolonged drug release in the lung. Specifically we have developed a particle platform 
around swellable hydrogel particles intended for inhalation (9, 19-21). The swellable 
particles have respirable aerodynamic size in dry state (i.e. during administration) but 
swell to larger geometric sizes after deposition in the hydrated wet respiratory tract, thus 
evading the macrophage uptake. Various cargos have been incorporated into these 
swellable particles, including the encapsulation of nanoparticles permitting  controlled 
drug release (22).  
In a recent formulation investigated in our laboratory, a copolymer of PEG grafted 
onto phthaloyl chitosan (PEG-g-PHCs) self-assembled nanoparticles were entrapped into 
Ca
2+
 cross-linked alginate to prepare respirable microparticles with semi-interpenetrating 
polymer networks (semi-IPN particles) for pulmonary sustained drug delivery. The 
preliminary in vitro evaluation of this hydrogel showed that it could be used as good 
potential carrier for pulmonary sustained drug delivery (15). Alginate is a natural, low 
toxicity, and biocompatible polyanionic polymer, composing of mannuronic acid (M) and 
guluronic acid (G) residues arranged linearly as consecutive G blocks (GGGGG), or 
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consecutive M blocks (MMMMM), or even alternating G and M blocks (GMGMGM) 
(23). The anionic alginate interacts with cationic chitosan (24), which is biocompatible 
and biodegradable polysaccharide (25) and is able to prolong drug release (26). In 
biomedical applications, alginate has been extensively investigated due to its unique 
ability to form hydrogel via ionotropic cross-linking with divalent cations such as Ca
2+ 
(27, 28). However, it has been recently reported that calcium in alginate hydrogel 
stimulates an inflammatory response (29), which is undesirable  in lungs for most 
therapeutic applications.  
For biomedical applications of alginate, there has been debate about the 
immunogenicity of the polymer despite the extensive evaluations both in vitro and in vivo 
(23, 30). One contention related to alginate immunogenicity is associated with the ratio of 
alginate blocks (31, 32). Alginate consists of both M-block and G-block. It was reported 
that alginate with a high ratio of M-block to G-block was more immunogenic and thus 
triggered an increased release of cytokines than that with high ratio of G-block to M-
block (33). In contrast, it has also been reported that no immunogenicity was observed 
when alginate with varied levels of M-block was investigated (34).  Alginate 
immunogenicity may also be related to the impurities in different sources or batches of 
alginate used. Alginate is extracted from natural resources. Thus impurities such as heavy 
metals, endotoxins, proteins and polyphenolic compounds may be present in alginate that 
could potentially cause an immune response (23). But, no foreign body reaction was 
observed when alginate was processed via multi-step purification technique in an animal 
model (30, 35). Therefore, based on the literatures, it appears that in some cases alginate 
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polymer may exert immunogenic responses, but in others, alginate appears to be non-
immunogenic. 
In this manuscript, a nano-in-micro hydrogel particle formulation was developed 
for sustained pulmonary drug delivery, which takes the advantages of both nanoparticles 
and swellable and respirable hydrogel particles.  Specifically we have developed an 
alginate hydrogel which was free of Ca
2+
. PEG-g-PHCs was synthesized and then self-
assembled into nanoparticles in combination with ciprofloxacin. The nanoparticle 
suspension was mixed with sodium alginate solution to form microparticle. In this 
microparticle, ciprofloxacin which was not incorporated into nanoparticles in the 
beginning would act as a cross-linker, similar to and replacing Ca
2+
, to form hydrogel 
with alginate. Subsequently, the hydrogel particles were spray dried to dry swellable 
nano-in-micro hydrogel particles, which were further evaluated with in vitro and in vivo 
experiments in rats by intratracheal insufflation.  
4.3 MATERIALS AND METHODS 
4.3.1 Materials 
4.3.1.1 Formulation study 
Chitosan (Cs) (MW: 4-5×10
5 
Da. %N-deacetylation: about 76.4 %), monomethoxy-
poly(ethylene glycol) (m-PEG, Mn 5,000 Da), succinic anhydride and 1-
hydroxybenzotrizole (HOBt) were obtained from Aldrich (Saint Louis, MO). 4-
Dimethylaminopyridine (DMAP) and ciprofloxacin were purchased from Sigma (St 
Louis, MO). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC.HCL) was provided by Fluka Chemical Corp. (Milwaukee, WI). Sodium alginate 
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(low viscosity; 250 cps for a 2% solution at 25
o
C), triethyl amine and other chemicals 
were obtained from Sigma-Aldrich (St Louis, MO). Phosphate buffer saline (PBS, pH 
7.4), absolute ethanol and all other reagents were of analytical grade and used as 
received. 
4.3.1.2 Cell culture 
Mouse macrophages cells, RAW 264.7 (8.8×10
5
 cells/mL) and Fetal bovine serum 
(FBS) were obtained from American Type Culture Collection, ATCC (Manassass, VA). 
Dulbecco’s Modified Eagle Medium (DMEM) was provided by Gibco (Grand Island, 
NY). 1 µm polystyrene (PS) particles (Fluospheres fluorescent (505/515) and 112 µm PS 
particles were purchased from Invitrogen (Eugene, OR) and Bangs Laboratories, 
Inc.(Fishers, IN), respectively. Paraformaldehyde (PFA, 4%) solution was obtained from 
USB Corporation (Cleveland, Ohio).  
4.3.1.3 Preliminary in vivo pharmacokinetic studies 
Lactose (Respitose
®
ML001) was obtained from DMV-Fonterra Excipients. 
Methanol and acetonitrile purchased from Fisher Scientific. Insufflator was provided by 
Penn-Century DP-4, Penn Century (Philadelphia, PA). 
4.3.2 Methods 
4.3.2.1 Preparation of PEG graft copolymerized onto phthaloyl chitosan (PEG-g-PHCs) 
The copolymer of PEG grafted onto phthaloyl chitosan (PHCs) was synthesized by 
a modified method reported in details in our earlier studies (9, 15), and described briefly 
as follows:  
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Firstly, PHCs was synthesized by reaction of 5 g of Cs with 22.5 g of phthalic 
anhydride in 150 mL of DMF at 130
o
C under dry nitrogen atmosphere for 10 h. The 
reaction mixture was left to reach room temperature and then the PHCs was precipitated 
over ice-water. The precipitated PHCs was filtered, washed with ethanol, and freeze 
dried. Secondly, m-PEG was converted into m-PEG-COOH through reaction with 
succinic anhydride. In brief, 10 g of m-PEG, 0.24 g of DMAP, 0.24 g of succinic 
anhydride, and 0.2 g of triethylamine were dissolved in 50 mL of dry dioxane. The 
reaction mixture was stirred at room temperature for 2 days under dry nitrogen 
atmosphere. The dioxane was evaporated and the residue (m-PEG-COOH) was taken up 
in CCl4, filtered and precipitated by diethyl ether. Lastly, the PEG-g-PHCs copolymer 
was obtained by stirring of 3.8 g of m-PEG-COOH with 0.5 g of the dried PHCs in 15 
mL DMF. Then, 0.3 g of the HOBt was added and the reaction mixture was stirred at 
room temperature until obtaining a clear solution. Afterwards, EDC·HCl (0.43 g) was 
added and the reaction was continued overnight under stirring at room temperature. The 
obtained PEG-g-PHCs copolymer was purified by dialysis in distilled water, washed with 
ethanol and freeze dried.  
4.3.2.2 Preparation of dry swellable nano-in-micro hydrogel particles  
The Ciprofloxacin-loaded swellable hydrogel particles were obtained via spray 
drying of a combination of ciprofloxacin-loaded PEG-g-PHCs nanoparticles suspension 
and sodium alginate solution. Briefly, homogenous solutions of the ciprofloxacin-loaded 
PEG-g-PHCs nanoparticles (1% w/v) and sodium alginate (3% w/v) were prepared using 
0.06% acetic acid and distilled water as solvents, respectively. The self-assembled PEG-
g-PHCs nanoparticles were prepared by sonication of 1% w/v PEG-g-PHCs solution 
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containing ciprofloxacin using a probe type sonicator (Misonix ultrasonic processor, S-
4000, Misonix Inc, CT) at 60 W for 2 minutes. The sonication step was repeated twice 
and performed in an ice-water bath. Then, a 75 mL of ciprofloxacin-loaded PEG-g-PHCs 
nanoparticles suspension was added dropwise with stirring to 25 mL of 3% aqueous 
alginate solution. The mixture was completed with distilled water up to a final 
concentration of 1.5% w/v. Then, the homogenized polymer mixture was spray-dried 
with a 0.7 mm two-fluid pressurized atomizer at a feed rate of 25% (6 mL/min) in a 
Büchi Mini spray dryer B-290 (Büchi, Switzerland). The atomizing air flow rate was 
500-600 NL/h. The inlet temperature was adjusted at 125ºC and the outlet temperature 
varied between 60ºC and 65ºC. The obtained hydrogel particles powder was collected 
and the spray drying yield (%) was calculated.  
4.3.2.3 Determination of particle size  
The size of the ciprofloxacin-loaded PEG-g-PHCs nanoparticles was estimated 
using dynamic light scattering (Wyatt Technology Corporation Dyna Pro-titan DLS) after 
sonication of a 1% PEG-g-PHCs solution containing ciprofloxacin for 2 minutes at a 
power of 60 watt. Size of micro hydrogel particles was determined using laser diffraction 
(SYMPATEC, Sympatec Gmbt, System Partikl-Technik, Germany, He-Ne laser beam 5 
mW max at 632.8 nm). The measurements were carried out in triplicates for the 
suspension of the micro hydrogel particles in acetone. Volume mean diameter (VMD, 
µm) was calculated from the particle size distribution curves for the micro hydrogel 
particles. Average aerodynamic diameter of the ciprofloxacin-loaded nano-in-micro 
hydrogel particles was also calculated using the following relationship (36): 
             𝒅𝒂𝒆𝒓 = 𝒅√𝝆                                                                     (1) 
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Where, daer is the micro hydrogel particles aerodynamic diameter (µm); d is the 
geometric diameter (VMD, µm); ρ is the micro hydrogel particles tapped density (g/cc). 
4.3.2.4 Morphology of micro hydrogel particles  
The morphology of the prepared dry swellable ciprofloxacin-loaded nano-in-micro 
hydrogel particles was examined by scan electron microscope (SEM) (Hitachi S-800 field 
emission scanning electron microscope operated in secondary electron mode with a 
Robinson backscatter detector and with a Hitachi PCI system for digital image capture). 
Dry particles were mounted on aluminum stubs with double-sided conducting carbon 
tapes and coated with a 50/50 mixture of Au/Pd to minimize surface charging. The 
samples were scanned at an accelerating voltage of 20 KV. 
4.3.2.5 Swelling study of micro hydrogel particles 
The swelling pattern of the developed dry ciprofloxacin-loaded nano-in-micro 
hydrogel particles in PBS, pH 7.4, was studied by determining the increase in both VMD 
(µm) and the median diameter (X50, µm) of the particles with time using laser 
diffractometer (SYMPATEC, Sympatec Gmbt, System Partikl-Technik, Germany).  
4.3.2.6 Investigation of next generation impactor (NGI) 
10 (±1) mg of powder, filled in size 3 Vcaps HPMC capsule, was dispersed through 
a commercial inhaler Handihaler® (Pfizer, Inc., USA; Boehringer  Ingelheim, Inc. 
Germany) into a next generation impactor (NGI, MSP Corp, MN) at a volumetric flow 
rate of 60 Lmin
−1
 actuated for 4-s. Drug content collected at each stage from the NGI 
apparatus was assessed via UV–VIS absorption spectroscopy at 280 nm. Emitted fraction 
(EF) was expressed as the total mass fraction of drug emitted from the inhaler. Fine 
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particle fraction (FPF) was defined as the drug mass (<5 μm) deposited in the NGI 
divided by the emitted dose. Respirable fraction (RF) was defined as the drug mass (<5 
μm) deposited in the NGI divided by drug mass recovered from the entire system. 
4.3.2.7 In vitro release of ciprofloxacin 
The in vitro release pattern of the ciprofloxacin from the developed nano-in-micro 
hydrogel particles was determined by transferring a certain weight (10-30 mg) of 
particles to a vial containing 1.5 mL of PBS, pH 7.4. Samples were maintained at 37
o
C 
with shaking at 100 rpm. At predetermined intervals, 100 μL aliquot was withdrawn and 
analyzed at max 280 nm using a UV-Vis spectrophotometry. The withdrawn aliquots 
were replaced with the same volume of fresh buffer, to keep the volume of the release 
medium constant. The amount of ciprofloxacin released (µg) from the swellable particles 
was then calculated using a standard curve of ciprofloxacin in PBS, pH 7.4. Results were 
expressed as cumulative release (%) relative to the initially loaded weight of 
ciprofloxacin in particles. The data points represent average (with standard deviation) 
from three independent experiments. 
4.3.2.8 Cytotoxicity assay of micro hydrogel particles 
The effect of the developed swellable ciprofloxacin-loaded nano-in-micro hydrogel 
particles on the viability of RAW 264.7 cells was investigated. Cells were seeded in 96-
well plates at 50,000 cells/well and incubated for 24 h at 37
o
C and 5% CO2. Fifty 
microliters of particles suspension (the total powder concentrations were 320, 800 and 
1600 µg/mL, respectively.) were incubated with cells for 24 h. Control group was the 
cells grown without adding swellable particles and the cytotoxicity of plain PEG-g-
NPHCs was also tested. The cell viability was estimated using a Microtiter tetrazolium 
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(MTT) cell proliferation assay kit provided by ATCC (Manassass, VA). After addition of 
the MTT reagent (10 µL), cells were incubated at 37
o
C and 5% CO2 for 4 h until the 
purple precipitate was visible. Afterwards, 100 µl of detergent reagent was added and 
cells were left in the dark at room temperature for 2 h. Cell viability was determined 
through recording absorbance at 570 nm. Data represents average absorbance of triplicate 
samples (with standard deviation).  
4.3.2.9 Preliminary in vivo pharmacokinetic studies  
Experimental design: Male Sprague-Dawley rats weighing 350 ± 30g were 
obtained from the Charles River, and maintained in 12 h light/dark cycle. Rats were 
acclimated for 3 days before the experiment and were allowed free access to standard 
food and water. Temperature and relative humidity were maintained at 25 ℃ and 50%, 
respectively. All animal procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC) of The University of Texas at Austin. All experiments related to 
animals were performed in according with the American Association for Accreditation of 
Laboratory Animal Care.  
Male Sprague-Dawley rats were randomly assigned to 2 groups, receiving 
formulation as follows: group 1, the powder mixture of micronized ciprofloxacin with 
lactose (ciprofloxacin concentration: 30% w/w); group 2, dry swellable ciprofloxacin-
loaded nano-in-micro hydrogel particle (ciprofloxacin concentration: 30% w/w). The 
dosage of ciprofloxacin was around 15mg/kg. 
Briefly, prior to dosing, all rats were anesthetized by IP injection of ketamine 
(75mg/kg) / xylazine (5mg/kg) cocktail. The footpads were pinched firmly to test the lack 
of pedal reflex. Each animal was placed flat on its back and the trachea was visualized 
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with the help of a laryngoscope. The insufflator (Penn-Century DP-4, Penn Century, 
Philadelphia, PA) was inserted into the trachea. The dry powder in the chamber of 
insufflator was dispersed with the help of 2 mL of air from an empty syringe. After 
insufflation, each animal was held in an upright position for 1 minute to ensure 
appropriate deposition of powder in the lung, then maintained at 30° during the 
recovering period on the heating pad. The insufflator containing the powder was weighed 
before, after powder filling, and after administration, to know the exact dose insufflated.  
4.3.2.10 Analysis of ciprofloxacin concentration in plasma, lavage and lung tissue 
For sampling after administration, a 0.4 mL blood sample was collected from the 
jugular vein. As for the lavage collection, animals were euthanized via CO2 inhalation 
and exsanguinated. The trachea was severed below the glottis between the thyroid glands, 
and was immediately cannulated and the lung was lavaged three times with 1 mL PBS 
(pH 7.4). The collected lavage was put in a 2 mL tube and kept in ice until analysis. 
Following lavage collection, the lung was removed, weighed and placed into a 50 mL 
conical tube, snap frozen and stored at -80 ºC until homogenization. For homogenization, 
lung tissues were thawed and 2 mL of PBS (pH 7.4) was added to each 50 mL tube. Lung 
was homogenized and the subsequent tissue slurry was analyzed for drug content.  
The concentrations of the ciprofloxacin in the plasma, lavage and lung tissue were 
measured by using a high performance liquid chromatography (HPLC) system with an 
UV detector at room temperature. An aliquot of sample was injected into an HPLC 
column (Atlantis T3 Column, 4.6 x 250 mm, 5 µm, Waters Corporation, MA, USA). The 
mobile phase consisted of a mixture of 800 mL of 50 mL/L acetic acid, 110 mL of 
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acetonitrile, and 90 mL of methanol per liter. The sample was detected under 280 nm 
with a flow rate of 1mL/min at room temperature. 
4.3.2.11 Statistical analysis 
The obtained data was analyzed and expressed as mean with standard deviation. 
Effects of various parameters were statistically analyzed by one-way ANOVA. 
Differences were considered significant at the level of p < 0.05.  
4.4 RESULTS AND DISCUSSION 
4.4.1 Preparation of the swellable ciprofloxacin-loaded nano-in-micro hydrogel 
particles   
One challenge for efficient pulmonary drug delivery is the lung physiological 
barriers (i.e., mucociliary escalator and alveolar macrophages), which should be 
considered thoroughly for the design of efficient pulmonary drug delivery systems. The 
preferred pulmonary delivery formulation should also possess controlled release profile 
along with minimal inactive excipients.  
In order to overcome the challenges, a novel antibiotic hydrogel particle with high 
drug loading was formed for controlled pulmonary drug delivery. As well known, 
alginate can interact with Ca
2+
 to form hydrogel. However, Ca
2+
 can stimulate immune 
effects as mentioned previously. Instead of using Ca
2+
, this study utilized ciprofloxacin, 
an antibiotic drug, as the cross-linker interacting with alginate directly and thereafter 
forming a high ciprofloxacin-loaded hydrogel particle system. In this high drug loading 
formulation, one fraction of ciprofloxacin was incorporated into PEG-g-PHCs 
nanoparticles; one fraction of ciprofloxacin was incorporated as a cross-linking agent for 
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alginate to form hydrogel, while the last fraction was physically entrapped in this 
hydrogel matrix (Scheme 1.). Hence, ciprofloxacin initially exhibited a burst release and 
reached a quick Cmax due to free ciprofloxacin physically entrapped in the hydrogel 
matrix. Meanwhile, the other fractions of ciprofloxacin acting as the cross-linker, as well 
as the ciprofloxacin encapsulated in the nanoparticles, were sustained, which has the 
potential to control drug release in lungs.  
The PEG-g-PHCs copolymer was synthesized through a modified method 
described in details in our previous study (9, 15). As illustrated in Scheme 2, the 
copolymer synthesis was achieved through firstly a phthaloylation process of the free 
amino groups of Cs to produce PHCs. FTIR spectrum of the PHCs (15) illustrated 
absorbance bands at 1395 and 732 cm
-1
 which were assigned for the aromatic C=C and 
C-H bonds of phthaloyl groups, respectively. Secondly, m-PEG was converted to m-
PEG-COOH using succinic anhydride. The modification of m-PEG was confirmed using 
EA and FTIR (15). Conjugation of m-PEG-COOH with PHCs was then carried out and 
the obtained PEG-g-PHCs was also characterized using various analytical techniques 
(15).  
The synthesized PEG-g-PHCs amphiphilic copolymer was utilized to prepare 
ciprofloxacin-free and ciprofloxacin-loaded self-assembled nanoparticles using 
sonication technique. Then, the resulting ciprofloxacin-loaded PEG-g-PHCs 
nanoparticles were incorporated into respirable micro hydrogel particles. These micro 
hydrogel particles were obtained via spray drying of a homogenous mixture of the 
ciprofloxacin-loaded PEG-g-PHCs nanoparticles and the aqueous alginate solution. The 
resulting nano-micro matrices were evaluated as carriers for sustained pulmonary 
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delivery of ciprofloxacin (ciprofloxacin concentration: 30% w/w) that combined the 
benefits of both nanoparticles and the micro hydrogel particles suggested in our previous 
studies (21). 
Calcium, a divalent ion with two positive charges, interacts with alginate linear 
chains to form a cross-linked hydrogel (28). This mechanism of crosslinking has been 
studied and been reported elsewhere (23). Recently, we found ciprofloxacin, similar to 
calcium, can also act as a cross-linker with alginate to form a stable hydrogel. Although 
ciprofloxacin is zwitterionic, different from calcium which is divalent, the charges of 
ciprofloxacin could be well adjusted. Ciprofloxacin has three pKa values, pKa1=5.1, 
pKa2=6.4 and pKa3=9.0 (37). Therefore, at a pH lower than 5, the ciprofloxacin 
molecule has two positive charges, similar to ionic calcium. In our hydrogel formation 
experiment, ciprofloxacin was kept in a solution with pH less than 5. 
4.4.2 Particle size  
The size of the prepared ciprofloxacin-loaded nanoparticles was found to be 218.6 
± 25.3 nm as determined by DLS. In the case of the prepared micro hydrogel particles, 
the volume mean diameters (VMD) of plain microparticles and ciprofloxacin-loaded 
nano-in-micro hydrogel particles were determined using laser diffraction and were found 
to be 2.1 ± 0.1μm, and 3.9 ± 0.1 μm, respectively. The developed particles showed 
relatively low tapped densities (0.298 g/mL and 0.347 g/mL for plain microparticles and 
ciprofloxacin-loaded nano-in-micro hydrogel particles, respectively). The theoretical 
aerodynamic diameters (da) of both ciprofloxacin-free and ciprofloxacin-loaded particles 
were also calculated using the volume diameters and particle densities and were found to 
be 1.2 ± 0.7 μm and 2.3 ± 0.1 μm respectively. Although the low da values of these 
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prepared particles would lead to high particles respirability the powder dispersion studies 
showed only modest aerosol performance of the pure powders. The powder dispersion 
performance of this dry powder, without added carrier particles, was assessed in vitro by 
a commercial inhaler Handihaler® via the Next generation impactor (NGI, MSP Corp, 
MN) at air flow rate of 60 ± 5%L/min. The fraction of powder deposited in each stage of 
NGI, capsule, device, adaptor, and throat was determined. It was found that respirable 
fraction (RF%) and fine particle fraction (FPF%) were 21.5% and 28.6%, respectively. 
The dispersibility of the pure powders was similar to currently marketed product 
performance values and was encouraging given the absence of any other carrier particle 
(i.e. lactose) which is well known to enhance the dispersibility of micronized powders 
(38) . 
In the control group, raw ciprofloxacin was jet-milled to achieve an X50 of 4.2 ± 0.5 
µm. The X50 is the median diameter of the particles on a volume basis (as determined by 
laser diffraction). The jet milling procedure was optimized such that this particle size 
could match the particle size of the dried swellable hydrogel particles. The swellable 
particles with ciprofloxacin in dried form had an X50 of 4.6 ± 0.1 µm.  
As a result of the similar particle size distribution of micronized ciprofloxacin and 
dried hydrogel particles, they represent well matched treatment and control groups in 
terms of particle size. In addition, insufflation, the method of directly spraying the 
dispersed powders into the lower airways of the animals, enables a direct comparison of 
the groups. This method of administration diminishes deposition differences between the 
two groups because the insufflator is placed intratracheally which avoids upper airway 
filtering on the basis of aerodynamic particle sizes. Thus, the deposition site of the two 
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kinds of particles in peripheral lung region after trachea insufflation should be similar. 
Therefore, after insufflation, differences in absorption and clearance of the two drug 
particles should be strongly related to particle size differences after wetting and swelling 
of the dried swellable particle, rather than the different deposition site of the two kinds of 
drug particles in the airways. 
4.4.3 Surface morphology  
Figure 1 shows the scanning electron micrographs of the developed micro hydrogel 
particles encapsulating ciprofloxacin-free and ciprofloxacin-loaded PEG-g-PHCs 
nanoparticles. As apparent from figure 1A, the ciprofloxacin-free hydrogel particles were 
generally spherical with relatively smooth surfaces. However, for the ciprofloxacin 
loaded particles, their surfaces were notably rougher (Fig 1B). The differences in surface 
roughness may be attributed to the additional crosslinking that occurs between the 
ciprofloxacin (for drug loaded particles) and the negatively charged sodium alginate 
chains during the spray drying process.  
4.4.4 Dynamic swelling study  
The swelling profile of the micro hydrogel particles incorporating ciprofloxacin-
loaded PEG-g-PHCs self-assembled nanoparticles in PBS, pH 7.4 was shown in Figure 2. 
The swelling profile of the developed hydrogel particles was obtained through 
determining the increase in the volume mean diameter (VMD, µm) of the particles at 
various time intervals using laser diffraction technique. As shown in Figure 2, the 
prepared hydrogel particles showed a fast initial swelling within the first few minutes. 
For instance, the VMD of the developed particles has increased from about 3 µm when 
dry to 22 µm after 2 minutes of swelling. This swelling continued regularly with time to 
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reach 41.9 µm at 14 minutes. The swelling can be attributed to the hydrophilic nature of 
the PEG side chains in the PEG-g-PHCs copolymer and the sodium alginate. As the 
swelling behavior demonstrated, the micro developed particles which had respirable 
aerodynamic sizes when dry showed large geometric sizes when swollen after a short 
period in simulated moist environment of the lung. We have studied this behavior in 
similar particles at shorter time scales and have also confirmed that particle swelling 
occurs slower than the calculated transport time of the particle in the high humidity of the 
airways. This enables the particles to remain small enough during their passage to the 
deep lung where they will be deposited. However, the swelling that occurs on the order of 
minutes, as shown in Figure 2,  enables the ciprofloxacin delivery systems to avoid 
macrophage uptake and at the same time confer sustained release of ciprofloxacin 
through a controlled polymeric architecture (9, 15, 20).      
4.4.5 In vitro cumulative release study 
The entrapment efficiency of ciprofloxacin in the developed swellable particles as 
quantified using UV-Vis spectrophotometry was found to be 30 % w/w. The in vitro 
release profile of ciprofloxacin from the developed swellable particles was illustrated in 
Figure 3. It was found that the investigated formulation showed a rapid initial release of 
ciprofloxacin (about 9%) within the first 5 hours followed by a relatively slow release up 
to 144 hours. The fast initial release may be due to the fast initial dynamic swelling of the 
investigated hydrogel particles as described in section 3.4. Several reasons are ascribed 
to the relatively slow and low release of the drug from the particles as observed in this in 
vitro assay. Firstly, a significant proportion of the ciprofloxacin present in the 
formulation will be bound to the alginate matrix and serves as a cross-linker. Therefore, 
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displacement of the ciprofloxacin by smaller monovalent cations will be necessary to 
enable release. In addition, the conditions of the release media were not selected to mimic 
physiological environment (i.e. release was performed in PBS pH 7.4). It is anticipated 
that more extensive release could be achieved in in vivo studies.  
4.4.6 Cytotoxicity assay 
The cytotoxicity of particles was determined using the MTT assay after the 
exposure of RAW 264.7 cells for 24 h to ciprofloxacin-loaded and plain PEG-g-PHCs at 
different concentrations (Figure 4). From the figure, at powder concentrations (i.e. 320 
µg/mL) of ciprofloxacin-loaded nano-in-micro hydrogel particles in which the 
ciprofloxacin and PEG-g-PHCs concentration were both around 106.6 µg/mL , the 
viability of the RAW 264.7 cells was reduced by 38.4% as compared to the control cells 
under the same experimental conditions. This reduction in cell viability might be 
primarily attributed to the drug (ciprofloxacin) rather than the excipients in particles since 
the viability of cells cultured with drug-free PEG-g-PHCs at 1000 µg/mL was 93.6%. 
4.4.7 Preliminary in vivo pharmacokinetic studies  
Plots of average ciprofloxacin plasma concentration versus time after 
administration of two dry powder formulations to male Sprague-Dawley rats were shown 
in Figure 5. As apparent from the figure, there was a statistical difference in plasma 
concentrations of ciprofloxacin when comparing the swellable particle formulation with 
the powder mixture formulation at all-time points (p < 0.05). The pharmacokinetic 
parameters were calculated by non-compartmental methods (39). For plasma, the areas 
under the curve (AUC0-7h) were 2.8 μg*h/mL, and 11.6 μg*h/mL for the group of 
swellable particles and the powder mixture group, respectively. For the Tmax, even no 
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exact value of Tmax could be achieved due to the limitation of time points, an estimation 
within the range of 0.25hr to 3 hr was determined. Overall, the mixture formulation 
showed much higher ciprofloxacin absorption into the plasma compared to the swellable 
particles, providing evidence for a delayed release from the swellable particles. 
In Figure 6, the drug concentration measured in lung lavage fluids was not 
significantly different between the two formulation groups at the initial time point (t = 
0.25 hr). As expected, with time going on lavage fluid drug concentrations decreased for 
both formulations. However, most notably ciprofloxacin decrease was observed in drug-
lactose binary mixtures. This rapid decrease could be explained by different amount of 
dissolved drug available for absorption. Compared to swellable particles for controlled 
drug release, there would be more drugs dissolved from simply drug-lactose mixture 
group, ready for absorption into lung tissue and/or plasma. Additionally, micronized drug 
in powder mixture group was engulfed easily by macrophages. Subsequently, the 
engulfed ciprofloxacin would be transported along the respiratory surface to the 
mucociliary escalator or to lung interstitium and lymph nodes (40-42). The low 
bioavailability of powder mixture group was also confirmed by the AUC results. As 
calculated from Figure 6, the ratio of AUC0-7h in lavage for swellable particles and 
control group was 1468.3 ± 377.5 µg*h/mL and 592.6 ± 139.9 µg*h/mL, respectively. 
These AUC data indicated that the swellable particles had significantly greater exposure 
to the lung fluid (p = 0.04) than the control group. 
In in vivo lung biodistribution studies, the drug concentrations in lung lavage are 
related to the unreleased drug. Therefore, in our studies, ciprofloxacin in lavage sample 
was regarded as unreleased drug from the dry swellable hydrogel particles. Based on this 
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assumption, we determined that over 50% of drug was released from the swellable 
particles in vivo. Specifically, it was estimated that approximately 50% of the drug had 
been released after 0.25 hours, and approximately 80% at 3 hours. 
Ciprofloxacin concentrations were also determined in the lung tissue samples. Lung 
concentrations were found to be higher for the swellable particles group than in the 
physical mixture group during the experimental period shown (Figure 7). The higher lung 
tissue concentrations from swellable particles could be attributed to two main factors. 
Firstly, the swellable particles formulation may extend the adhesion time between 
particles and lung epithelial cells, decreasing the particle clearance of mucociliary 
escalator in respiratory tract. Secondly, the release of the ciprofloxacin nanoparticles 
from the micro hydrogel particles can explain differences in the lung tissue levels. 
Nanoparticles may be more likely to be accumulated in the epithelial cells than free drug 
(as evidenced by the rapid plasma absorption of the free ciprofloxacin formulation). 
Further studies are required to determine the exact mechanisms of lung tissue 
distribution. Finally, the slightly different aerosol dispersion characteristics of the two 
treatment powders may also result in differences in deposition profiles (although this was 
minimized using the direct insufflation technique used in these studies) but may lead to 
small differences absorption and clearance from the lung.   
4.8 CONCLUSION 
In the present study, the self-assembled ciprofloxacin nanoparticles were 
encapsulated a dry swellable nano-in-micro hydrogel particles which were free of Ca
2+
. 
This formulation displayed suitable aerodynamic characteristics and sustained drug 
release profile. When delivered to rats, it enabled ciprofloxacin to achieve a low systemic 
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exposure but maintained higher concentrations in the lung for more than seven hours. 
Further formulation optimization and studies focused at the cellular mechanisms of 
absorption and clearance are required.  
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Figure 4.1 Scanning electron micrographs of (a) plain microparticles (no ciprofloxacin); 






Figure 4.2 Dynamic swelling pattern of the swellable nano-in-micro hydrogel particles in 














Figure 4.4 The effect of different concentrations (320, 800 and 1600 µg/mL) of the 
developed swellable ciprofloxacin-loaded nano-in-micro hydrogel particles on the 
viability of RAW 264.7 macrophage cells. Cells were seeded at 50,000 cells/well and 
incubated with the particles for 24 h at 37
o






Figure 4.5 Time-course of concentration of ciprofloxacin in plasma. (♦),swellable 
ciprofloxacin-loaded nano-in-micro hydrogel particles; (■), powder mixture of 






Figure 4.6 The concentration of ciprofloxacin in lung lavage. (■), swellable 
ciprofloxacin-loaded nano-in-micro hydrogel particles; (■), powder mixture of 













Figure 4.7 The concentration of ciprofloxacin in rat lung tissue. (■),swellable 
ciprofloxacin-loaded nano-in-micro hydrogel particles; (■), powder mixture of 
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Chapter 5: Drug Cross-Linked Hydrogel Particles for Controlled 
Pulmonary Drug Delivery 
5.1 ABSTRACT 
The current antibiotic therapies for treating pulmonary infections are usually dosed 
multiple times per day. Despite wide interests in developing controlled aerosol 
formulations, successful developments of controlled pulmonary drug delivery have been 
limited. The objective of this study was to form controlled drug release hydrogel dry 
powder suitable for pulmonary administration where the drug itself was utilized as the 
hydrogel cross-linker. The benefits of this novel approach were that the hydrogel dry 
powder would be calcium free, have high drug loading, and release the drug in a 
sustained manner. Alginate-ciprofloxacin hydrogel was first developed, then spray dried 
to form a dry powder. The hydrogel dry powder was characterized by scanning electron 
microscopy, laser diffraction, X-ray diffraction, and transmission electron microscopy. In 
vitro drug release studies were performed in a Transwell
®
 model. The aerosol 
performance of the dry powder was investigated using the next generation impactor. The 
alginate hydrogel dry powder system exhibited high ciprofloxacin loading (57%) and a 
geometric size of less than 5 µm. Ciprofloxacin was present in the amorphous state in the 
dry powder and was released in a controlled release manner relative to ciprofloxacin 
alone, i.e. 80% of drug released at 8 hours. The hydrogel dry powder also achieved a high 
fine particle fraction (above 45%) as determined by the in vitro aerosol performance 
study. A novel inhalable alginate hydrogel dry powder system was successfully 
formulated and this discovery indicates broader applications for other antibiotics in the 




The pulmonary delivery of antibiotics is a promising approach for the treatment of 
local lung infections (1, 2). For the current marketed antibiotic formulations, however, 
the requirement of multiple drug administrations per day in order to achieve a therapeutic 
effect limits their applicability (3).To reduce administration frequency, controlled 
pulmonary release formulation is a strategy that can maintain an effective and consistent 
local drug concentration and therefore prolong the time period between doses (4, 5). 
Previously, several types of controlled pulmonary release formulations for antibiotic 
delivery have been investigated, such as liposomes (6) and polymer based microparticles 
(i.e. PLGA) (7). However, due to the similarity of lipid materials in liposomes to the cell 
membrane, the interaction of the liposome with the lung cells may potentially increase 
the drug toxicity to the lung cells.by interacting with the lung cells (8). In addition, for 
the PLGA formulation, the process of formulation production always involves an organic 
solvent, which gives rise to the concern of residual solvent in the final product (9). Most 
importantly, these particles with an optimal aerodynamic diameter range targeted to the 
alveolar region (i.e. 0.5<da<5 µm) will be rapidly cleared by the alveolar macrophages. 
This is because the geometric diameters of these particles are usually less than 6 µm, 
which is the preferable size range for uptake by the alveolar macrophages  (10).  
The approach we employed in the current study was to form swellable hydrogel dry 
powder by utilizing the unique benefits of hydrogel: higher drug payload, larger 
geometric diameter after swelling, and sustained drug delivery (11-13). Hydrogel is a 
well-studied formulation in biomedical applications, and now begins its new era in 
pulmonary delivery (14).  In the peripheral respiratory system, many alveolar 
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macrophages exist in the alveolar region. Alveolar macrophages can phagocytos 
exogenous particles as a self-defense system, which largely reduces the effectiveness of 
inhaled drug particles. Alveolar macrophages prefer to select particles with a geometric 
size range of between 0.5-5 µm, a size that overlaps with most size range of respirable 
particles (10).  For hydrogel, its ability to easily hydrate will allow it expand and 
effectively avoid uptake by macrophages. Therefore, the critical issue of respiratory 
clearance in developing functional inhalation formations will be compromised by 
fabricating hydrogel in dry state (15).  
Alginate hydrogel is most frequently prepared using ionic cross-linking with a 
divalent agent (i.e. Ca
2+
) (16). However, a recent study revealed the potential side effect 
that the calcium ions in calcium alginate gels may up-regulate the IL-1β secretion from 
the surrounding tissues of injection sites in mice (17).  To provide solution to this 
potential problem, we propose a method to form a novel alginate hydrogel that has no 
calcium. We hypothesize that ciprofloxacin, an antibiotic, can directly interact with 
alginate, playing the role of a cross-linker (instead of calcium) in order to form the 
alginate hydrogel. In addition, this type of hydrogel particle will show a size range small 
enough for deep lung delivery. Upon contacting the lung surface, the particles will 
rehydrate and swell. This enables the particles to undergo significant increases in their 
geometric size within the lungs, thus eluding rapid clearance by alveolar macrophages. 
The aim of this study was to achieve a formulation with a high drug loading, the 
merits of no Ca
2+
 related toxicity, and a simplified manufacturing process. The 
formulation described in this paper can also release the drug in a sustained manner, as 
expected with a hydrogel. In this novel formulation, one part of ciprofloxacin will 
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disperse uniformly through the hydrogel matrix, and another part of ciprofloxacin will 
ionically interact with alginate chains causing them to polymerize. Based on the two 
different ways of holding the drug in the hydrogel, the alginate-ciprofloxacin hydrogel 
dry powder is able to release the drug from the hydrogel matrix in a sustained manner, 
thereby reducing the administration frequency.  
5.3 MATERIALS AND METHODS 
5.3.1 Formation of Alginate Hydrogel 
Alginate hydrogel was prepared by first forming an alginate-ciprofloxacin gel 
suspension followed by high speed homogenization. A volume of 30 mL of ciprofloxacin 
HCl solution (1.6% w/v, Letco, Decatur, AL) was added to 150 mL of alginate solution 
(0.16% w/v, Protanal CR8223, FMC Biopolymer, PA). Deionized water was used to 
prepare each of the solutions. Immediately upon addition, the two components formed an 
amorphous gel. This suspended gel was then homogenized using a rotor stator 
homogenizer (polytron PT2000, Kinematica, Switzerland). The homogenizer was 
operated at 11,000 RPM for 20 minutes using an ice bath to minimize temperature 
increase. The resulting homogenized gel suspension comprised of ciprofloxacin HCl and 
sodium alginate at a weight ratio of 1.5:0.75. The pH of this suspension sample was also 
determined (Accumet®, Fisher Scientific). The resultant gels and controls were evaluated 





5.3.2 Competition Study of Binding Capacity to Alginate between Ciprofloxacin and 
Calcium 
To understand the mechanism of alginate gelling in the presence of ciprofloxacin, a 
competitive binding study between ciprofloxacin and calcium ions (i.e., Ca
2+
) was 
performed. In this study, a solution composed of both calcium chloride and ciprofloxacin 
HCl was added into alginate solution (0.5% w/v),  followed by high speed 
homogenization (11000 rpm for 20 seconds). The mole ratio of calcium to ciprofloxacin 
in the suspension was varied from 0:1 to 6:1. The resultant suspensions were then 
centrifuged at high speed (10000 rpm for 5mins, Hettich 320R, MA) to collect the 
supernatant. The free ciprofloxacin concentrations present in the supernatant were 
determined with UV-Vis (Infinite® M200, Tecan, CA).  
5.3.3 Spray Drying to Form Alginate-Ciprofloxacin Hydrogel Dry Powder  
Sodium alginate (0.5% w/v) and ciprofloxacin HCl (1% w/v) solutions were 
prepared in deionized water. The ciprofloxacin solution was then added into the alginate 
solution to yield a weight ratio of 1.0:0.75 (ciprofloxacin:alginate) to form a gel 
suspension via high speed homogenization as previously described. The pH value of 
suspension was determined to be approximately 5.7. The gel suspension was 
subsequently spray dried to form dry powder (BÜCHI B-290, BÜCHI Labortechnik AG, 
Switzerland). Spray drying was performed under the following parameters: 135°C inlet 
temperature, 68°C outlet temperature, 357 L/h air flow, 35 m
3
 aspiration rate, and a feed 
pump flow of 5-10 mL/min.  Figure 1 illustrated the process of spray drying to form the 




5.3.4 Scan Electron Microscopy (SEM) 
The scanning electron microscopy (Supra 40VP, Zeiss, Germany) was used to 
visually assess the size and morphology of the alginate hydrogel dry powder. The coating 
conditions for the tested samples were 15 nm of Pd/Pt via sputter coating.  
5.3.5 X-Ray Diffraction (XRD) 
X-ray powder diffraction (XRD) studies were performed to investigate the crystal / 
amorphous forms of ciprofloxacin in the alginate-ciprofloxacin hydrogel dry powder. 
Samples were run on a Philips 1710 X-ray diffractometer equipped with a copper target 
and a nickel filter (Philips Electronic Instruments, Inc., Mahwah, NJ). The voltage and 
current of the equipment were set as 40 KV and 40 mA, respectively. Samples were 
placed on a metal cell and flattened by using a glass slide prior to XRD analysis. The 2θ 
angle, step size, and dwell time were 5−50°, 0.05°, and 2 seconds, respectively.  
5.3.6 Transmission Electron Microscope (TEM) 
A drop of the alginate-ciprofloxacin hydrogel dry powder suspended in ethanol was 
placed on a carbon-coated copper grid and then dried under room temperature. The 
uncoated sample was directly investigated by a transmission electron microscope (JEOL, 
2010F, Peabody, MA).  
5.3.7 Swelling Study of Alginate-Ciprofloxacin Hydrogel Dry Powder 
The swelling of the alginate-ciprofloxacin hydrogel dry powder was studied by 
determining the increase of the median diameter (X50, µm) of the hydrogel dry powder in 
deionized water after a 2 minute suspension period. The measurement was taken using a 
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laser diffractometer (SYMPATEC, Sympatec Gmbt, System Partikl-Technik, Germany). 
The size of hydrogel dry powder in ethanol was tested as control. 
5.3.8 In Vitro Drug Release Study 
To evaluate the release profile of ciprofloxacin from the alginate-ciprofloxacin 
hydrogel dry powder, a Transwell assay was used.  In short, a predetermined amount of 
powder was placed on a semi-permeable polycarbonate membrane (12 mm diameter 
insert, 0.4 µm pore size) on the donor compartment of a Transwell
®
 insert (Corning, NY). 
To ensure that the release profile was not influenced by the intrinsic solubility limit of 
ciprofloxacin in this study (200 µg/mL, (18)), 1 mL of PBS (pH 7.4) was applied to 
disperse the dry powder (approximately 250 µg of dry powder, equivalent to 130 µg of 
ciprofloxacin) on the donor compartment. The Transwell
®
 receptor contained 8 mL of 
PBS. The Transwell
®
 device was then incubated at 37 °C without stirring (19). Aliquots 
(0.2 mL) of the PBS were taken from the receptor compartment at different time points 
within the period of 0 to 8 hours. Another 0.2 mL of fresh PBS was immediately put back 
into the receptor compartment to maintain a constant volume of release medium. As a 
control group, 1 mL of spray dried ciprofloxacin dry powder suspension in PBS (125 
µg/mL) was directly placed onto the donor compartment. The collected samples were 
tested via UV-Vis at 280 nm. In a similar study, deionized water was used as the release 
medium instead of PBS, while the operational conditions were kept the same.  
5.3.9 In Vitro Aerosolization Study 
10 (±1) mg of powder, filled in the size 3 Vcaps HPMC capsule (Capsugel, CA), 
were dispersed through a commercial inhaler Aerolizer
®
 (Novartis, Switzerland) into a 
next generation cascade impactor (NGI) (Copley Scientific, UK) operated at a volumetric 
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flow rate of 60 Lmin
−1
 and actuated for 4 seconds. Drug content collected at each stage 
from the NGI apparatus was assessed via UV–Vis absorption spectroscopy at 280 nm. 
Fine particle fraction (FPF) was defined as the drug mass (<5 µm) deposited in the NGI 
divided by the emitted dose.  
5.3.10 Statistical Analysis 
The obtained data were analyzed and expressed as means with standard deviations. 
Effects of various parameters were statistically analyzed by t-tests. Differences were 
considered statistically significant at the level of p < 0.05. 
5.4 RESULTS  
5.4.1 Formation of Alginate Hydrogel 
As shown in Figure 2, after adding ciprofloxacin HCl solution droplets into alginate 
solution, an opaque gel formed around the introduced ciprofloxacin droplets. It was 
observed that over time the interior of the introduced droplet became increasingly opaque. 
In addition, the gels formed by the addition of the ciprofloxacin droplets became more 
dense than the solution and sedimented at the bottom of the vial. After the addition of all 
the ciprofloxacin solution, the gels were heterogeneously distributed in the alginate 
solution. Homogenization was used to uniformly distribute the gel and reduce the size of 
the gels.  
As shown in Figure 3A, alginate was observed to be a clear solution prior to the 
addition of ciprofloxacin HCl. In contrast, when a specific amount of ciprofloxacin was 
added into the alginate solution (Figure 3B, the weight ratio of drug to alginate was 
1.5/0.75), chain-like structures were observed. Multiple chains bundled together could 
130 
 
also be observed (highlighted in the Figure 3B).  As the amount of ciprofloxacin added 
increased, the formation of these bundles was increasingly observed. As a control, Figure 
3C showed the alginate solution adjusted to a pH of 5.5 with HCl to match the pH of the 
alginate-ciprofloxacin mixture in Figure 3B.  At this low pH there are no observable 
structures without the addition of ciprofloxacin.   
5.4.2 Competition Study of Binding Capacity to Alginate between Ciprofloxacin and 
Calcium 
From the competitive binding study between ciprofloxacin and calcium ions 
(Figure 4), it was observed that approximately 60% of ciprofloxacin was encapsulated 
into the alginate hydrogel matrix when no calcium was present (i.e., the mole ratio of 
ciprofloxacin to calcium was 1.0:0). When the mole ratio of ciprofloxacin to calcium was 
1.0:0.5, there was no significant difference in ciprofloxacin encapsulation compared to 
calcium free gels. However, as the ratio of calcium to ciprofloxacin increased, the 
encapsulation percentage of ciprofloxacin in the alginate hydrogel matrix decreased 
significantly.  
5.4.3 Scanning Electron Microscopy  
Scanning electron microscopy (SEM) was conducted to characterize the 
morphology of this alginate hydrogel dry powder containing ciprofloxacin as cross-linker. 
Figure 5C showed the morphology of the alginate-ciprofloxacin hydrogel dry powder 
produced from the alginate-ciprofloxacin gel suspension. The dry powders were observed 
to be collapsed spheres with an irregular shape. The individual particles had smooth 
surfaces with a size of less than 5 µm. Figures 5A and 5B illustrated the morphology of 
raw ciprofloxacin and alginate, respectively.  
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5.4.4 X-Ray Diffraction  
In Figure 6, line A represented the crystal peaks of raw ciprofloxacin HCl. Line D 
showed the spectrum of alginate-ciprofloxacin dry powder. In contrast to line A, the 
representative crystal peaks of ciprofloxacin HCl were not present, but replaced with a 
broad peak at 24° to 28° (line D). As a control, the physical mixture of alginate with 
ciprofloxacin (line C) showed similar peaks as raw ciprofloxacin (line A), while raw 
alginate did not show any peaks (line B).  
5.4.5 Transmission Electron Microscopy  
TEM was conducted to investigate the existence of crystal ciprofloxacin in the 
alginate-ciprofloxacin hydrogel dry powder. As shown in Figure 7A and 7B, the alginate-
ciprofloxacin hydrogel dry powder did not contain ciprofloxacin in crystal form, but 
rather in an amorphous form on the scale of 10 nm. The presence of the amorphous form 
of ciprofloxacin in the hydrogel dry powder was also confirmed by the absence of an 
electron diffraction pattern illustrated in Figure 7C. The presence of diffraction circles in 
the electron diffraction patterns of TEM can confirm the existence of crystals in the tested 
materials (20).  
5.4.6 Swelling Study of Alginate Hydrogel Dry Powder 
The swelling profile of the alginate-ciprofloxacin hydrogel dry powders was 
investigated using laser diffraction. The initial diameter of the hydrogel dry powder 
before swelling was approximately 4.1 µm. After 2 minutes in deionized water, the 




5.4.7 In Vitro Drug Release Study 
The in vitro drug release profiles of ciprofloxacin from the alginate-ciprofloxacin 
hydrogel dry powder were illustrated Figure 8. In Figure 8A, deionized water served as 
the release medium. The initial release rate of ciprofloxacin at the 0.25 h time point was 
the same for the ciprofloxacin dry powder and the alginate-ciprofloxacin dry powder. At 
longer time points however, there was a more rapid release of ciprofloxacin from the 
ciprofloxacin dry powder when compared to the alginate-ciprofloxacin hydrogel dry 
powder. The alginate-ciprofloxacin dry powder resulted in a slow release pattern of 
ciprofloxacin.  
Figure 8B shows the release profiles of ciprofloxacin in PBS release medium. The 
release pattern of ciprofloxacin dry powder in the PBS was similar to that in deionized 
water. However, an increased release profile was detected from alginate-ciprofloxacin 
dry powder in PBS in contrast to that in deionized water. For the ciprofloxacin dry 
powder, 90% of the ciprofloxacin was released by 8 hours with 50% released in 1 hour. 
For the alginate-ciprofloxacin hydrogel dry powder, the 50% release time was 
approximately 4 hours.   
5.4.8 In Vitro Aerosolization Study 
The in vitro aerosol performance of alginate-ciprofloxacin hydrogel dry powder 
was assessed. The fractions of powder deposited in each stage of NGI, device (capsule, 
Aerolizer
®
, adaptor), induction port were determined (Figure 9). It was found that the fine 
particle fraction (FPF %), mass median aerodynamic diameter (MMAD) and were 46.8% 




Ciprofloxacin displays both concentration-dependent and time-dependent 
antibacterial effects (21). However the AUC/MIC ratio has been reported to be the most 
efficient method to evaluate the antibiotic activity of fluroquinolones (22). Therefore, a 
larger AUC obtained from the development of a controlled release formulation will 
potentially benefit the management of lung infections, particularly when the drug is 
locally administered to achieve a high drug concentration at the site of infection. 
5.5.1 Mechanisms of Ciprofloxacin Mediated Gelling of Alginate.  
Ciprofloxacin has three pKa values associated with its piperazinyle substituent 
structure, which are: pKa1=5.1, pKa2=6.4 and pKa3=9.0 (23). Therefore, depending on 
the pH of the surrounding environment, ciprofloxacin will have three distinct charged 











. The pH value of the gel 
suspension obtained following homogenization of the drug-alginate mixture (the weight 
ratio of drug to alginate is 0.75/0.75) was about 5.8, indicating that around 70% of 
ciprofloxacin would exist as ciprofloxacin·H
+
 (24). The mono-cationic charge in 
ciprofloxacin·H
+
 will interact with anionic charge in alginate (25). When more 
ciprofloxacin HCl was added to the alginate solution, the pH value in the suspension 
(Figure 2B, the weight ratio of drug to alginate is 1.5/0.75) would be decreased to 5.5, 
and the divalent cationic form of Ciprofloxacin·H2
2+
 will appear (23). At this pH, the 
extra positive charges present on Ciprofloxacin·H2
2+
 will interact with the negative 
charges present on the adjacent alginate chains.  Therefore, under these conditions, 
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ciprofloxacin facilitates the formation of junction zones and the drug acts as a cross-
linker instead of the traditional Ca 
2+
 (Figure 2B).    
We have previously reported a similar swellable hydrogel dry powder for 
controlled pulmonary drug delivery. In that research, ciprofloxacin was firstly 
encapsulated into PEGylated chitosan nanoparticles which were then spray dried with 
alginate to form swellable and inhalable nano-in-microparticles for pulmonary drug 
delivery.  The encapsulation efficiency for loading ciprofloxacin into the PEGylated 
chitosan nanoparticles was approximately 15% (The total ciprofloxacin loading 
efficiency in the nano-in-microparticles was around 30%.), and the free ciprofloxacin 
functioned as a cross-linker and interacted with the alginate. Due to the low loading 
efficiency of ciprofloxacin in these chitosan nanoparticles, as well as the complex and 
costly process of making PEGylated chitosan, here we directly combined ciprofloxacin 
with alginate to form a hydrogel dry powder without the addition of chitosan. We 
simplified the preparation method for these hydrogel microparticles, decreased the 
potential risk that polymeric chitosan may pose to lung tissue, and increased the 
ciprofloxacin loading efficiency from 30% to 50% in the final microsized hydrogel dry 
powder.   
5.5.2 Competition Study between Ciprofloxacin and Calcium 
As seen in Figure 4, when the mole ratio of ciprofloxacin to calcium was 1.0:0.5, 
the Ca
2+
 ions could interact with the alginate to form an alginate-calcium hydrogel via 
binding to the sites in the alginate chains where no ciprofloxacin had attached. This 
alginate-calcium hydrogel trapped some free ciprofloxacin inside the hydrogel matrix, 
leading to less free ciprofloxacin in the supernatant after centrifugation. However, with 
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the addition of more calcium into the suspension, Ca
2+
 ions began to compete with 
ciprofloxacin for the binding sites in the alginate chains where ciprofloxacin was bound. 
The significant decrease of ciprofloxacin encapsulation in the alginate matrix indicates 
that the binding capacity of calcium to alginate is stronger than that of ciprofloxacin, 
resulting in more ciprofloxacin molecules in the supernatant after high-speed 
centrifugation.  
5.5.3 X-Ray Diffraction  
As indicated in line D, representing the alginate-ciprofloxacin hydrogel dry powder, 
from Figure 6, the representative crystal peaks of ciprofloxacin HCl disappeared and 
were replaced with a broad peak pattern at 24° to 28°.  This suggests that the 
ciprofloxacin molecule exists in an amorphous state in the alginate-ciprofloxacin 
hydrogel dry powder (26). The amorphous state of ciprofloxacin in the hydrogel dry 
powder can be easily explained.  Prior to spray drying process, one portion of 
ciprofloxacin, approximately 60%, binds molecularly to alginate chains via ionic 
interactions between the positive charges of ciprofloxacin and the negative charges of the 
alginate chains. The other portion of the ciprofloxacin molecules is uniformly dispersed 
in the suspension of the alginate-ciprofloxacin system. During the spray drying process, 
the ionic interaction between ciprofloxacin and alginate is not influenced by the short 
period of heat. Therefore, the ciprofloxacin molecules binding with the alginate chains 
still molecularly interact with the alginate matrix after spray drying. The uniformly 
dispersed ciprofloxacin in the suspension is distributed evenly throughout the entire final 
hydrogel dry powder, either dispersed within the hydrogel matrix or located on the 
surface of hydrogel dry powder, as shown in Figure 1. XRD spectra showed the broad 
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peak of amorphous ciprofloxacin and therefore, both groups of ciprofloxacin (bound and 
unbound) were molecularly scattered throughout the alginate hydrogel dry powders. 
5.5.4 In Vitro Drug Release Study 
As shown in Figure 8A, in the deionized water release medium, less than 20% of 
the ciprofloxacin was released from the alginate-ciprofloxacin hydrogel dry powder 
before 8 hours. The slow release pattern may be explained by the fact that deionized 
water contains many fewer ions than PBS buffer. Therefore, no ions in the deionized 
water release medium can replace the ciprofloxacin ions and bind to the alginate chains 
(27). Consequently, the ciprofloxacin ions will firmly bind to alginate chains, leading to a 
slow release pattern of ciprofloxacin from the ciprofloxacin-alginate hydrogel dry powder.   
The initial release pattern of less than 10% of the drug is attributable to the portion 
of ciprofloxacin attaching to the particles’ surfaces or dispersing in the regions that are 
close to the surface after spray drying. This portion of drug is released with the 
hydrogel’s swelling process upon interacting with the release medium.  Even though the 
hydrogel dry powder could swell in the deionized water, it still kept a spherical shape 
through the end of the drug release test, indicating that ciprofloxacin is capable to cross-
link alginate chains for a long period of time. In the PBS release medium, sodium and 
potassium ions in the release medium could interfere with the ionic interaction between 
the positively charged ciprofloxacin and negatively charged alginate chains, or even 
replace the ciprofloxacin ions as crosslinkers. Because of that, the ciprofloxacin was 
released relatively quickly from the hydrogel dry powder in PBS compared to that in 
deionized water.  
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Simulated lung fluid would better mimic the real lung physiological conditions. In 






, etc., which 
could potentially influence the release pattern of ciprofloxacin from this dry powder 
formulation. More interestingly, the presence of Ca
2+
 in the simulated lung fluid will 
trigger the ciprofloxacin release from the dry powder due to the competition between the 
calcium ions and the ciprofloxacin. Oppositely, the Ca
2+
 will also cross-link the alginate 
chains via ionic interactions to form a calcium based hydrogel, which could tighten the 
alginate powder matrix and subsequently hinder the diffusion of ciprofloxacin from the 
inside of the powder to the outmost layer. This remains to be seen and future studies will 
focus on these different possibilities.  
5.5.5 Consideration of Therapeutic Dosage for Controlled Pulmonary Delivery 
Due to the advantages of the respiratory system for local and systemic drug 
delivery, controlled release pulmonary formulations are becoming attractive. However, 
there is no controlled-release formulation for inhalation approved by FDA. This is mainly 
ascribable to the untested long-term safety profile of many of the excipients that could 
potentially be used (28-30). In general, it is polymer excipients that contribute to a 
prolonged drug release profile. Thus, a large mass fraction of polymer in the controlled 
release dosage form may be administered daily to patients via inhalation to the lung 
region. However, few polymers are in the approved excipients list for inhalation usage. 
Therefore, the application of unapproved polymers in controlled release pulmonary 
formulations will require extensive toxicity testing (14).  
Alginate is one of most commonly used natural polymers to form hydrogels in 
biomedical applications. However, despite the extensive evaluations both in vitro and in 
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vivo, there is still a deep concern regarding immunogenicity of alginate (27, 31). One 
concern is associated with the ratio of alginate blocks (32). Alginate is composed of 
unbranched copolymer that contains two blocks, the M-block and the G-block. It has 
been reported that alginate with a high ratio of M-block to G-block is more immunogenic, 
and therefore may trigger an increased release of cytokines than that with high ratio of G-
block to M-block (33). In contrast, no immunogenicity was detected from alginate with 
varied levels of M-block (34). Due to the different sources or batches of alginate used, its 
immunogenicity may also be related to the impurities left during the extraction process 
from natural resources. Thus impurities such as heavy metals, endotoxins, proteins and 
polyphenolic compounds may be present in alginate, and these may cause an immune 
response (27). Therefore, highly purified alginate with fewer impurities can decrease its 
potential immunogenicity in biomedical applications. For example, no foreign body 
reaction was observed in animals when alginate was processed via a multi-step 
purification technique (31, 35). In the current study, alginate was crossed-linked with 
ciprofloxacin to form hydrogel designed for pulmonary delivery. More studies are 
ongoing in our lab to investigate the interaction between alginate polymer and respiratory 
cells.  
5.6 CONCLUSION 
In the present study, we developed an alginate-ciprofloxacin hydrogel dry powder 
that was free of Ca
2+
 and exhibited a high ciprofloxacin loading with a high fine particle 
fraction suitable for deep lung delivery. Upon interacting with moisture, this hydrogel dry 
powder in the dry state will rehydrate and swell to a larger geometric size therefore 
avoiding macrophages in the lungs. In addition, ciprofloxacin, as a cross-linker to interact 
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with alginate chains, was present in the amorphous state and exhibited a sustained 
released from the hydrogel dry powder.  
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Figure 5.1 Diagram of the spray drying process used to form the alginate-ciprofloxacin 












Figure 5.3 Microscopy of chain-like structures in the alginate-ciprofloxacin hydrogel 
system.  A. Alginate solution when no ciprofloxacin was added; B. Suspension of 
alginate-ciprofloxacin system, the weight ratio of alginate to ciprofloxacin was 1.5:0.75, 






Figure 5.4 Competition study of binding capacity to alginate between calcium and 
ciprofloxacin; *, p < 0.05, t-test compared to the percentage of ciprofloxacin in the 






Figure 5.5 Scanning electron microscopy of spray dried alginate-ciprofloxacin hydrogel 
dry powder. A. Ciprofloxacin HCl crytals; B. Sodium alginate powder; C. Spray dried 






Figure 5.6 X-ray diffraction patterns of spray dried alginate-ciprofloxacin hydrogel dry 
powder. A. Ciprofloxacin HCl crystals; B. Sodium alginate powder; C. Mixture of 
ciprofloxacin HCl with sodium alginate powder (57% w/w of ciprofloxacin), D. Spray 







Figure 5.7 Transmission electron microscopy of spray dried alginate-ciprofloxacin 
hydrogel dry powder (57% w/w of ciprofloxacin in dry powder). A, B, C, were the 







Figure 5.8 In vitro drug release profiles of Alginate-ciprofloxacin hydrogel dry powder. 
A. Drug release profile in deionized water B. drug release profile in PBS. *, p < 0.05 






Figure 5.9 In vitro aerosol profile of spray dried alginate-ciprofloxacin hydrogel dry 
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Chapter 6: Polyethylene Glycol Conjugated Tobramycin Improved 




The eradication of microbial infections is extremely challenging due to the recalcitrant 
nature of the causative microbial biofilms. The objective of this study was to develop a 
functionally enhanced antibiotic that would improve the therapeutic activity against 
bacterial biofilms. Here we explore the hypothesis that by reducing the affinity of an 
antibacterial toward biofilms would result in improved efficacy of this antibacterial.  To 
test this hypothesis, a conventional antibiotic, tobramycin, was chemically conjugated 
with 5000 kDa polyethylene glycol (PEG) via site specific conjugation to form a novel 
form of PEGylated-tobramycin (Tob-PEG). The antibacterial efficacy of Tob-PEG, as 
compared to that of the non-conjugated tobramycin, was assessed on the planktonic phase 
and biofilms phase of Pseudomonas aeruginosa (P. aeruginosa) using a standard biofilm 
assay.   The minimum inhibitory concentration (MIC80) of Tob-PEG was higher (13.9 
µmol/L) than that of tobramycin (MIC80, 1.4 µmol/L) in the planktonic phases of P. 
aeruginosa. In contrast, the Tob-PEG was approximately 3.2 fold more effective in 
eliminating bacterial biofilms than tobramycin. Specifically, Tob-PEG had minimum 
inhibitory concentrations lower than those exhibited by tobramycin (MIC80 27.8 µmol/L 
vs 89.8 µmol/L). Confocal laser scanning microscope and scanning electron microscope 
findings further confirmed these data.  Thus, modification of antimicrobial as by 
PEGylation (Tob-PEG) appears to be a promising approach for overcoming the bacterial 
resistance in the established biofilms of P. aeruginosa.  The mechanisms by which the 
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conjugated Tob-PEG enhances the elimination of P. aeruginosa biofilm are currently 
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Cystic fibrosis (CF) is an autosomal recessive genetic disorder that most 
prominently affects the airways. This chronic and debilitating disease is caused by a 
mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene and 
leads to an impaired mucociliary clearance mechanism(1). Due to this impaired clearance 
and subsequent susceptibility to infection, an inflammatory response, characterized by 
recruitment of polymorphonuclear leukocytes (PMN) and stimulation of antibody 
production (1, 2), is mounted.  This increased inflammation then leads to further disease 
manifestation commonly described as the “downward spiral” in cystic fibrosis (3). 
Despite aggressive antibiotic treatment, the elimination of chronic P. aeruginosa 
infections in CF lungs is extremely difficult (4, 5). The pathogen often adapts to resist 
both the host inflammatory defense mechanisms and externally applied antibiotic therapy, 
often allowing for the formation of microbial biofilms (6-8). 
Biofilms are complex, functional communities of one or more species of 
microorganisms that are encased in extracellular polymeric substances (EPS) and 
attached to both a solid surface and to each other (9). The effective dose of an 
antimicrobial needed to eliminate biofilms can be up to 1000 times greater than that of 
the planktonic phase (10, 11). The slow growth rates (12), low antibiotic penetration (13), 
high cell density (10), excessive extracellular matrices (14), pH alterations (15), 
mutations (16) and altered nutrient requirements (17) are well-known properties that 
cause this high antimicrobial resistance in microbial biofilms.  P. aeruginosa usually 
starts colonizing in the airway in CF patients as a non-mucoid strain in their early stages 
of life. As the infection progresses, the pathogen switches to a virulent mucoid form that 
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secretes excessive amounts of EPS (18, 19), which consists of an abundance of 
polysaccharides, proteins, and DNA (20). The resulting biofilms are thick, pathogen 
embedded, and highly resistant to common therapeutic agents currently used in CF 
infections such as beta-lactams, ciprofloxacin, tobramycin and colistin (14, 21-29). 
Tobramycin is a broad spectrum aminoglycoside antibiotic commonly used in 
treating P. aeruginosa infections (30, 31). Tobramycin binds the 30S and 50S subunits of 
bacterial ribosomes thereby preventing the formation of 70S ribosomes. As a result, 
bacterial mRNA cannot be translated into proteins, leading to microbial cell death (32). 
There are two FDA approved tobramycin formulations for the management of CF 
patients, including tobramycin inhalation solution (TOBI
®
) and tobramycin inhalation 
powder (TOBI
® 
Podhaler™) (33, 34). Despite the broad-spectrum antibacterial effects 
and benefits of inhalation, resistance to tobramycin treatment in these patients occurs 
regularly (13, 19, 24-26, 35). 
 Thus, the development of newer antimicrobial agents with superior abilities to 
eliminate the established chronic biofilm associated with CF infections remains the 
utmost priority in CF therapy (36, 37). Our hypothesis, derived from the proposed 
mechanisms of biofilm resistances, is that reducing the binding or affinity of the 
antibacterial toward the biofilm itself will result in improved antibiotic efficacy.  To test 
this hypothesis, a conventional antibiotic, tobramycin was chemically modified. 
Tobramycin has previously been demonstrated to bind to biofilm matrices (38), thus 
reducing the effective concentration of antimicrobial able to reach the pathogenic 
organisms, as well as limiting the penetration of the antibacterial agent to the deeper 
microstructure of the biofilm, thereby creating an undesirable stress response in the 
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pathogen (17, 39). It is essential to improve the penetrative capabilities of existing 
antimicrobials, such as tobramycin, in order to overcome thick biofilm barriers and to 
achieve superior elimination of P. aeruginosa biofilms. Modifying existing drugs by 
conjugating them to polymers has been widely reported to improve the efficacy of 
existing drugs (40-42). Predominantly, conjugation to polyethylene glycol (PEG) has 
been used to increase plasma half-lives of therapeutic agents (43, 44). PEGylation has 
also been shown to improve diffusion of nanoparticles through mucus (45). To our 
knowledge, the conjugation of PEG to tobramycin has not been reported in the literature, 
but its feasibility is supported by reports that have shown that chemical modification at 
the 6’ amine group of tobramycin will still maintain antibacterial activity (46).  
Thus, the aim of this study was to conjugate tobramycin with PEG and compare the 





6.3 MATERIALS AND METHODS 
6.3.1 Synthesis of Tob-PEG  
Tob-PEG was prepared according to a modified method as shown in Figure 1 (47-
49). Briefly, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (1mmol, 
EDC·HCl, AnaSepc Inc., Fremont, CA, USA) and N-Hydroxysuccinimide (1 mmol, 
NHS, Aldrich, St. Louis, MO, USA) were added into a 50 mL triangular flask containing 
15 mL PBS buffer with PEG-COOH (0.5 mmol, synthesized in our lab as described 
previously) (50) and stirred overnight at room temperature. After that, tobramycin sulfate 
(0.8 mmol, Letco, Decatur, AL, USA) was added and stirred overnight under similar 
conditions. The resulting product was dialyzed against distilled water and subsequently 
lyophilized. Nuclear Magnetic Resonance (NMR) spectra of the final product of Tob-
PEG were recorded (Varian DirectDrive 400 spectrometers) at 400MHz in the NMR 
facility of the Department of Chemistry & Biochemistry of The University of Texas at 
Austin. 
6.3.2 Microbial Culture  
Pseudomonas aeruginosa (P. aeruginosa) PAO1 (kindly provided by Dr. Marvin 
Whiteley at The University of Texas at Austin) was used throughout the study.  Blood 
agar (Sigma Aldrich, St. Luis, MO, USA) and Brain Heart Infusion (BHI, Sigma Aldrich, 
St. Luis, MO, USA) broth were used for culturing P. aeruginosa. 
Prior to each experiment, P. aeruginosa were cultured on blood agar for 18 h at 
37
°
C. BHI was inoculated and incubated for 18 h at 37
°
C in an orbital shaker (150 rpm, 
VWR
®
 Incubating Orbital Shaker, VWR international, Radnor, PA, USA). The resultant 
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bacterial growth was harvested, washed twice with phosphate buffered saline (PBS, pH 
7.4, Sigma Aldrich, St. Luis, MO, USA), and resuspended in BHI. The concentration of P. 
aeruginosa was adjusted to 1×10
7 
cells/mL by spectrophotometer (Infinite M200, 
TECAN systems Inc., San Jose, CA, USA) and confirmed by hemocytometric counting.  
6.3.3 Biofilm Formation   
P. aeruginosa biofilm was formed as previously described with minor 
modifications (51). A commercially available sterile, polystyrene, flat bottom 96-well 
microtiter plate (BD Biosciences, CA, USA) was used throughout the biofilm studies. 
First, 100 µL of standard bacterial suspension (10
7
 cells/mL) was transferred into each 
well of 96-well microtiter plate, and incubated for 90 min in an orbital shaker (37
°
C, 80 
rpm) to promote microbial adherence to the wells. After the initial adhesion phase, each 
well was aspirated then was gently washed twice with PBS to remove loosely adherent 
bacterial cells. Then, 200 µL of BHI was added to each well, and the plate was incubated 
for 24 h in an orbital shaker (37
°
C, 80 rpm). Prior to evaluation of each therapeutic agent, 
supernatant in the each well was aspirated and the biofilm was washed twice with PBS to 
eliminate excess media.  
6.3.4 Determination of Minimum Inhibitory Concentration (MIC80) 
6.3.4.1 The P. aeruginosa Planktonic Phase 
Bacterial suspension (5×10
5
 cells/mL) in designated wells of a 96-well microtiter 
plate was treated with each therapeutic agent in a concentration gradient (2-fold dilution) 
and incubated for 24 h at 37
°
C. At the end of this incubation, bacterial growth was 
measured by optical density using a spectrophotometer at 595 nm. For each agent, the 
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lowest concentration at which 80% of bacterial growth was inhibited was considered the 
MIC80 against P. aeruginosa. Each experiment was conducted in quadruplicates on three 
different occasions. 
6.3.4.2 The P. aeruginosa Biofilm Phase 
 P. aeruginosa biofilms were developed as described in the biofilm formation 
section. After 24 hours, biofilms were gently washed as mentioned above, and each test 
agent, including tobramycin, PEG, a physical mixture of PEG and tobramycin, Tob-PEG 
and PBS (as control) were added to the biofilms at various predetermined concentrations. 
The plates were then incubated with these test compounds for another 24h in an orbital 
shaker (37
°
C, 80 rpm).  At the end of the incubation, an XTT reduction assay was 
performed to quantify the viability of the biofilms. This experiment was conducted in 
quadruplicates on three different occasions. 
6.3.5 XTT Reduction Assay 
After incubation of biofilms with each tested reagent, a standard XTT reduction 
assay was performed to measure the viability of biofilms by means of bacterial cell 
metabolic activity (52, 53). In brief, commercially available XTT powder (Sigma, St. 
Louis, MO, USA) was dissolved in PBS by 1 mg/mL, sterile filtered (0.22 µm pore size 
filter), and stored at -70
°
C. Fresh 0.4 mM menadione solution was prepared prior to 
experiment. Before the assay, XTT solution was thawed and mixed with menadione 
solution at 20:1 (v/v). Then, 158 μL of PBS, and 42 μL mixture of XTT and menadione 
solution were immediately added into each well containing bacterial biofilms, and 
allowed to incubate in the dark for 3 h at 37
°
C. The color intensity of the resultant 
solution was measured by a spectrophotometer at 492 nm. 
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6.3.6 Visual Alginate and Drug Interaction Study  
A simple assay was developed to visually demonstrate the differences in interaction 
between the different drugs and formulations used in these performance studies. A 
volume of 50 µL alginate solution (0.5 g/100 mL) was applied to a glass slide. One drop 
of drug or control (tobramycin, PEG, unbound mixture of tobramycin with PEG, Tob-
PEG) was added to the top of alginate solution on the glass slide using a micropipette. 
Immediately after applying the drop of drug solution, the slide was examined by light 
microscopy imaging at 15 times magnification on a Planapo 2.0X microscope (Leica 
M205 FA, Germany). All test samples were applied at a concentration of 1.4 mmol/L. An 
untreated alginate solution, PEG, and the physical blend of PEG and tobramycin were 
used as the control groups.  
6.3.7 Confocal Laser Scanning Microscopy 
P. aeruginosa biofilms were grown on glass cover slips placed in the bottom of 6-
well plate (BD Biosciences, USA) as previously described (51). The biofilms were gently 
washed with PBS and treated with the test agents (tobramycin, PEG, Tob-PEG and PBS) 
at their respective MIC80 calculated for the biofilms,(51) and incubated for 24 h in an 
orbital shaker (37
°
C, 80 rpm). Biofilms on cover slips in each well were then stained with 
Live and Dead stain (Live/Dead BacLight Bacterial Viability kit, Invitrogen, Eugene, OR, 
USA) and imaged by confocal laser scanning microscopy (Leica TCS SP5, Leica 
Microsystems, IL, USA). 
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6.3.8 Scanning Electron Microscopy (SEM) 
 Biofilms were prepared for SEM as previously described (54). P. aeruginosa 
biofilms were formed on the glass cover slips in a 6-well plate and treated with the 
different test agents (PBS, tobramycin, PEG, and Tob-PEG) as previously described in 
the methods of confocal laser scanning microscopy. After a 24 h incubation, the cover 
slips were removed from the well, gently washed twice with PBS, and fixed with an 
aldehyde mixture in an ice bath for 3 h then were exposed to reduced osmium tetroxide in 
a microwave (2 min on, 2 min off, 2 cycles, Pleco Biowave, 100 w). The cover slips were 
then washed in distilled water, and dehydrated in a series of ethanol washes (50%, 70%, 
95%, and 100%, 10 min each) and finally dried in a critical point dryer (> 40 
°
C, > 1200 
psi, Samdri-790 Critical point Dryer, Tousimis Research Co., MD, USA). Finally, the 
cover slips were coated with Platinum/Palladium (Cressington sputter coater 208 HR, 
Cressington Scientific Instruments Ltd, UK) and surface topography of the biofilms 
formed on the cover slip was visualized with scanning electron microscope (Zeiss Supra 
40VP, CA, USA) in high-vacuum mode. 
6.3.9 Statistical Analyses 
During the determination of MIC80, the broth dilution assay gave rise to the same 
specific drug concentration that caused 80% inhibition of P. aeruginosa at each of the 
biological and technical replicates, therefore generating a zero standard deviation. This is 






6.4.1 Synthesis and Characterization of Tob-PEG Conjugate 
 Figure 2B shows representative H-NMR spectra for tobramycin, PEG, and Tob-
PEG, illustrating the successful synthesis of the conjugated Tob-PEG.  In Figure 2B, the 
multiplets at around 5.45 ppm were assigned to the H at A1’, while multiplets at 4.90 
ppm corresponded to the H at C1’’. The two H at A3’ had two correlations with the 
signals at about 2.10 ppm and 1.75 ppm, and the two H at B2 were linked with the peaks 
at about 2.05 ppm and 1.45 ppm. Compared to the H-NMR spectrum of tobramycin, the 
peaks from 1.4 ppm to 2.1 ppm shifted slightly to left in the H-NMR spectrum of Tob-
PEG, which was due to the interference of the PEG5k. The peaks at 5.50 ppm and 4.95 
ppm in the H-NMR spectrum of Tob-PEG matched well with that of Tobramycin as 
described above. These characterized peaks of tobramycin were absent in the H-NMR 
spectrum of PEG5k. Multiplets overlapped with each other within the range of around 3 
ppm to 4 ppm, which was attributed to the polymeric structure of PEG. 
6.4.2 Antibacterial Activity in the Planktonic and Biofilms 
One of the major objectives of conjugation of tobramycin with PEG was to achieve 
superior antibacterial effects as compared to just tobramycin. However, according to the 
broth microdilution assay, tobramycin was still more effective than Tob-PEG in 
inhibiting the planktonic P. aeruginosa growth as manifested by the respective MIC80, 
1.4 µmol/L.  
As revealed by an XTT reduction assay, which directly assessed bacterial cell 
metabolic activity, Tob-PEG demonstrated a significantly lower MIC80 against mature P. 
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aeruginosa biofilms when compared to tobramycin (27.8 µmol/L vs 89.8 µmol/L). Tob-
PEG was at least 3 fold more efficient than tobramycin. Physically mixed tobramycin and 
PEG (ie. not conjugated) exhibited MICs similar to tobramycin alone (89.8 µmol/L) 
against mature biofilms. Chemical conjugation of tobramycin and PEG led to favorable 
antibacterial activities over tobramycin in mature biofilms. 
6.4.3 Visual Alginate and Drug Interaction Study 
As shown in Figure 4A, the microscope image of the control, untreated alginate 
solution was clear and transparent. In Figure 4B, the added drop of drug immediately 
produced a visible boundary between the added drug droplet and the alginate solution. 
This spherical formation did not dissipate with time. In Figure 4D, the mixture of non-
conjugate PEG with tobramycin resulted in a similar visible interaction between the 
added drop and the alginate solution, though the boundary dispersed more than with 
tobramycin alone. In Figure 4C, however, the added droplet containing Tob-PEG did not 
result in a visible boundary. The same was observed for the added PEG solution (Fig. 4E). 
6.4.4 Confocal Laser Scanning Microscopy 
The mature P. aeruginosa biofilms, characterized using confocal microscopy, were 
densely colonized with hierarchically and three-dimensionally structured formations as 
shown in Figure 5A. Biofilms were observed to have a significant amount of extracellular 
polymeric substances with a high live/dead cell ratio (Fig. 5A).  Even though the biofilms 
treated with PEG alone (Fig. 5B) visually appeared to be thinner, there were no 
significant changes observed when compared to the control biofilms (Fig. 5A). In 
contrast, mature biofilms treated with tobramycin at its MIC80 (for biofilm phase) showed 
a greater reduction of total biofilm with a scanty architecture. A higher proportion of 
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dead cells with lower quantities of extracellular materials were seen after treatment with 
tobramycin (Fig. 5C). Most significantly, the P. aeruginosa biofilm treated with Tob-
PEG exhibited only a few isolated bacterial colonies instead of a recognizable biofilm 
structure.  Additionally, no extracellular material was visible and the biofilm architecture 
was completely disrupted when compared to all other treated biofilms (Fig. 5D). Thus, 
these qualitative findings further confirmed that the newly synthesized Tob-PEG 
molecule possessed superior antibiofilm properties over traditional tobramycin. 
6.4.5 Scan Electron Microscopy (SEM) 
Despite the modification of biofilms caused by the necessary preparation 
techniques using in the SEM imaging of biofilms, SEM still revealed differences between 
Tob-PEG and tobramycin treated biofilms. Similar to the confocal images, control P. 
aeruginosa biofilms exhibited dense colonization with a clearly visible extracellular 
matrix. These biofilms showed highly organized and well defined architecture (Fig. 6A). 
PEG treated biofilms also exhibited a similar dense and well organized extracellular 
matrix further confirming that PEG itself did not significantly affect the overall structure 
of P. aeruginosa biofilms (Fig. 6B). Both tobramycin and Tob-PEG treated biofilms at 
their respective MIC80s demonstrated significant disruption of the biofilm structure. 
However, tobramycin treated biofilms showed some evidence of organization throughout 
the remaining bacterial cells with some quantities of extracellular matrix visible (Fig. 6C). 
In contrast, only a few scattered bacterial cells were noted in Tob-PEG treated biofilms 
(Fig. 6D). This showed that the chemical conjugation of PEG to tobramycin had a 
significant negative effect on the P. aeruginosa biofilm structure and matrix when 




As introduced above, biofilms are well known to be extremely resistant to 
antimicrobials. Hence, the principal objective of most novel anti-biofilm strategies is to 
develop antimicrobials that are more efficient at killing biofilms under lower therapeutic 
doses.  To achieve that objective, we have tested aforementioned compounds on 
established P. aeruginosa biofilms.  
6.5.1 Tob-PEG Exerted a Superior Antibiofilm Effect on the P. aeruginosa Biofilms 
When Compared to Tobramycin 
Tob-PEG showed greater anti-biofilm properties over conventional tobramycin 
towards biofilms. The results obtained from the biofilms phase confirmed these findings. 
Despite lower activity in the planktonic phase as indicated by a higher MIC80, Tob-PEG 
had significantly improved (over 3 fold) activity the in the biofilms with low MIC80 (Fig. 
3).  To rule out the possibility of the increased inhibitory properties of tobramycin due to 
physical presence of PEG in the formulation, a mixture of both tobramycin and PEG was 
also investigated. This physical mixture failed to elicit similar significant effect as 
chemically conjugated tobramycin and PEG. These data confirmed that the process of 
chemical conjugation and the final structure of the novel molecule was an important 
factor for the antibiofilm activity.   
 It is well-known that biofilms exhibit resistance to antimicrobials via 
nonspecifically binding to biofilm matrix (38). This slow penetration results in cascade of 
phenotypic changes, which allows the adjacent bacteria to trigger stress responses and 
become resistant to the specific agent administered. For tobramycin, the higher MIC80 
observed in the biofilms is likely ascribed to the ionic interactions between tobramycin 
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and biofilm matrix. This interaction limits the penetration of tobramycin through the 
alginate matrix in P. aeruginosa biofilms and impacts its therapeutic efficacy (38). In 
contrast, the PEG moiety in the Tob-PEG molecule has a relatively large molecular 
weight (5000 Da) and appears to form a molecular shield to cover the cationic charges in 
tobramycin. As previously reported, PEGylation of particles enables enhanced 
penetration of substances through charged matrices such as mucins (45). Therefore we 
hypothesize that tobramycin is converted to a new therapeutic form, with less binding 
affinity to biofilm matrix, upon the covalent addition of a PEG moiety. This allows for 
greater penetration into the interior of the biofilm and therefore lowers MICs.  
MICs in the planktonic phase of microorganisms are typically reported as MIC90 or 
MIC100. In biofilms, however, resistance to antibiotic treatments results in very high drug 
concentrations required to achieve this 90% or above death of the bacteria (16, 58). 
Therefore, in most experimental cases, if not all, achieving these high concentrations is 
unpractical and extremely difficult due to chemical and physical properties of the specific 
drug (ie. solubility limits, tonicity effects, etc.). Therefore, unlike their planktonic 
counterparts, there are no established standards such as Clinical and Laboratory 
Standards Institute (CLSI) guidelines for measuring MICs of biofilms. MIC80 values of 
antimicrobial agents had been increasingly used in recent studies focusing on biofilms as 
an acceptable parameter (59, 60). Accordingly, MIC80 was used in the current study as a 
standardized measure of antibacterial efficacy for comparisons between the different 
treatments.  
Consistent with the antimicrobial activity, the microscopy studies presented here 
also displayed a significant difference between tobramycin and Tob-PEG treatment in the 
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P. aeruginosa biofilms. Both live and dead staining, confocal microscopy, and SEM 
images confirmed that tobramycin and Tob-PEG could severely disrupt the biofilm 
architecture. However, the destruction resultant from the Tob-PEG treatment was more 
severe than that of only tobramycin, as the biofilms treated with tobramycin showed a 
certain degree of preservation of the three-dimensional architecture and extracellular 
matrix (Fig. 6C). The microscopic images also confirmed that PEG itself did not 
significantly affect P. aeruginosa biofilms. 
6.5.2 Tob-PEG Did Not Benefit the Elimination of Planktonic P. aeruginosa 
Aminoglycosides, the family of antibiotics that tobramycin belongs to, are 
hydrophilic sugars with amino and hydroxyl functional groups (61). The amine moieties 
of aminoglycosides become protonated in physiological conditions making 
aminoglycosides polycationic. Due to this polycationic nature, aminoglycosides like 
tobramycin exhibit a greater affinity of binding to bacterial nucleic acids. Particularly, 
aminoglycosides possess a high affinity to certain portions of RNAs, such as prokaryotic 
16S rRNA (61). The latter, a small ribosomal subunit, has been identified as the primary 
target of aminoglycosides. Aminoglycoside binding to 16S rRNA impairs “translational 
proofreading” giving rise to misreading or premature termination of the RNA message, or 
both. Subsequently, an inaccurately translated protein product is resulted. This subset of 
abnormal proteins can subsequently be incorporated into the cell membrane of a 
bacterium, leading to altered permeability and up regulation of amino acid influx. This 
cycle continues until cell death occurs (32, 62). 
When tested in the planktonic phase, Tob-PEG showed approximately 10 fold 
reduction of its efficacy in achieving MIC80 compared to conventional tobramycin (Fig. 
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3). This is not an unexpected finding given that the 5000 kDa PEG attached to the 
tobramycin is likely to influence antibacterial activity via several mechanisms. Firstly, 
the conjugation of PEG to the tobramycin molecule can diminish the binding efficiency 
of tobramycin to 16S rRNA by the steric hindrance introduced by the addition of a PEG 
compared to the non-conjugated tobramycin. Secondly, the conjugation of PEG to the 6’ 
amine group of tobramycin yielded a molecule, Tob-PEG, with a decreased cationic 
nature, as shown in Figure 4, thereby decreasing electronic interactions of the drug and 
the target ribosome. Thirdly, the process of cellular uptake of tobramycin into the 
bacteria has been reported to be self-promoted, which involves the aminoglycoside-
induced disruption of Mg
2+
 bridges between adjacent lipopolysaccharide molecules in the 
outer membrane of the bacteria (63, 64). Thus, the conjugation of PEG to tobramycin 
may significantly affect this uptake mechanism and consequently decrease its cellular 
uptake. These potential reasons for the lower antimicrobial activity of Tob-PEG in the 
planktonic phase of P. aeruginosa will be explored further. Moreover, it is important to 
note that PEG alone, as a control, did not cause any significant changes to P. aeruginosa 
growth in the planktonic phase indicating that PEG itself was neither an inhibitor nor 
promoter of microbial activity (65).   
6.5.3 Visual Alginate and Drug Interaction Study 
It has been previously reported tobramycin may bind to alginate in the bacterial 
biofilm through ionic interactions (38). This binding has been proposed to limit the 
permeation of tobramycin into the biofilm and subsequently result in lower drug 
concentrations reaching the bacterial cell target site (66). This has been suggested as one 
potential reason for bacterial biofilm antibiotic resistance. In this study, our working 
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hypothesis was that the conjugation of PEG to tobramycin would diminish the positive 
charge of tobramycin and consequently diminish the ionic interactions between alginate 
and tobramycin thereby facilitating the permeation of tobramycin into the bacterial 
biofilm. Beyond the antibacterial performance studies, we performed studies that 
illustrated the clear difference in drug interactions with alginate using the PEG conjugate. 
As shown in Figure 4C, no visible interaction with alginate was observed after 
tobramycin was chemically modified into Tob-PEG in contrast to the unconjugated drug 
(Fig. 4B). The absence of interaction can be attributed to the PEG conjugated at the 
tobramycin 6’ amine site, which reduces the overall positive charge of tobramycin. In 
addition, the polymeric PEG, which has a molecular weight of 5000 kDa, is proposed to 
form a hydration shield around the tobramycin, which would also decrease the likelihood 
of physical interactions between the tobramycin and alginate. This is illustrated by the 
differences in the interactions observed in Figure 4C and 4D. In Figure 4D, the droplet of 
the added mixture of tobramycin and PEG dispersed more easily into the alginate than 
was observed with tobramycin alone. This indicated that PEG, even unbound to the 
tobramycin could achieve some level of shielding, though significant interactions were 
still observed.  
6.6 CONCLUSION 
To overcome biofilm-associated antibacterial resistance, a new compound of 
tobramycin-PEG (Tob-PEG) was developed via conjugating tobramycin to polyethylene 
glycol (PEG). Compared to tobramycin, Tob-PEG exhibited almost 10 fold less 
inhibition efficiency on P. aeruginosa in its planktonic phase. However, Tob-PEG 
suppressed P. aeruginosa growth in its biofilm phase with much lower concentration than 
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tobramycin (27.8 µmol/L vs. 89.8 µmol/L). The mixed PEG and tobramycin (ie. non-
conjugated) behaved as same as tobramycin, indicating that the covalently bound 
complex Tob-PEG does have unique qualities. The novel compound presented and 
characterized here, Tob-PEG, provides a promising direction for overcoming bacterial 
resistance due to biofilm formation, a key to developing further therapies for congenital 
conditions such as CF. Additional investigations are currently underway to further 
understand the mechanisms for improved efficacy of this compound., as well as the 
combination usage of tobramycin and Tob-PEG on P. aeruginosa biofilms. 
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Figure 6.1 Schematic illustration of synthesis of polyethylene glycol conjugated 
tobramycin (Tob-PEG). 
Abbreviations: PEG, polyethylene glycol; Tob-PEG, polyethylene glycol conjugated 
tobramycin; EDC, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide; NHS, N-








Figure 6.2 H-NMR spectrum of tobramycin, PEG5K, and Tob-PEG5k in D2O. A, 
chemical structure of tobramycin with marked H atoms at different locations; B, H-NMR 
spectrum of tobramycin, PEG5K and Tob-PEG5k. 






Figure 6.3 Minimum inhibitory concentration (MIC80) of tobramycin and Tob-PEG in 
planktonic phase and biofilm phage of P. aeruginosa. (MIC80±SD, SD=0, n=12, 
Experiments were performed in quadruplicates three times. The broth dilution assay 
resulted in the same value of the drug concentration for MIC80, thus SD was 0.) 








Figure 6.4 Visual alginate and drug interaction study. A, alginate solution droplet; B, 
interaction between alginate and tobramycin; C, interaction between alginate and Tob-
PEG; D, interaction between alginate and the mixture of tobramycin and PEG; E, 
interaction between alginate and PEG. Bar: 2.0 mm.  
Abbreviations: Tob, tobramycin; PEG, polyethylene glycol; Tob-PEG, polyethylene 











Figure 6.5  Confocal images of P. aeruginosa biofilm. Stained with Live/Dead BacLight 
Bacterial Viability kit. Live cells were stained in green and dead cells stained in red. A, 
control P. aeruginosa biofilms; B, biofilms treated with PEG; C, biofilms treated with 
tobramycin; D, biofilms treated with Tob-PEG. 







Figure 6.6 SEM images of P. aeruginosa biofilm (×10000). A, control P. aeruginosa 
biofilms; B, biofilms treated with PEG; C, biofilms treated with tobramycin; D, biofilms 
treated with Tob-PEG.  
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